

PEDIATRIC EMERGENCY MEDICINE PRACTICE

AN EVIDENCE-BASED APPROACH TO PEDIATRIC EMERGENCY MEDICINE ▲ EBMEDICINE.NET

Pediatric Pain Management in the Emergency Department

Abstract

Adequate analgesia is critical in the management of pediatric patients in the emergency department. Suboptimal treatment of pain can have deleterious effects in the short term, and it can also affect a patient's development and reaction to future painful experiences. Tools exist to quantify a patient's pain level regardless of age or developmental stage. Both pharmacologic and nonpharmacologic methods can be effective in the management of pediatric pain. Emergency clinicians must remain vigilant in the recognition, treatment, and reassessment of pediatric pain, as patients' developmental level may limit their ability to independently express their pain experience without prompting or tools. This issue reviews pain scales that are suitable for pediatric patients and discusses pediatric pain management using non-pharmacologic methods, topical, local, and regional anesthesia as well as systemic agents.

August 2019
Volume 16, Number 8

Authors

Neil Uspal, MD, FAAP

Associate Professor, Department of Pediatrics, University of Washington, Seattle, WA

Kelly D. Black, MD

Attending Physician, Emergency Medicine, Cook Children's Medical Center, Fort Worth, TX

Stephen John Cico, MD, MEd, FACEP, FAAP, FAAEM

Assistant Dean for Graduate Medical Education & Faculty Development, Associate Professor of Clinical Emergency Medicine & Pediatrics, Fellowship Director for Pediatric Emergency Medicine, Departments of Emergency Medicine & Pediatrics, Indiana University School of Medicine, Indianapolis, IN

Peer Reviewers

Samina Ali, MD, FRCPC

Professor, Pediatrics & Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada

Naveen Poonai, MSc, MD

Associate Professor, Departments of Paediatrics and Internal Medicine, Schulich School of Medicine & Dentistry, London, Ontario, Canada

Prior to beginning this activity, see "CME Information" on the back page.

This issue is eligible for 2 Pharmacology and 4 Pain Management CME Credits

Editors-in-Chief

Ilene Claudius, MD

Associate Professor; Director, Process & Quality Improvement Program, Harbor-UCLA Medical Center, Torrance, CA

Tim Horeczko, MD, MSCR, FACEP, FAAP

Associate Professor of Clinical Emergency Medicine, David Geffen School of Medicine, UCLA; Core Faculty and Senior Physician, Los Angeles County-Harbor-UCLA Medical Center, Torrance, CA

Editorial Board

Jeffrey R. Avner, MD, FAAP

Chairman, Department of Pediatrics, Professor of Clinical Pediatrics, Maimonides Children's Hospital of Brooklyn, Brooklyn, NY

Steven Bin, MD

Associate Clinical Professor, UCSF School of Medicine; Medical Director, Pediatric Emergency Medicine, UCSF Benioff Children's Hospital, San Francisco, CA

Richard M. Cantor, MD, FAAP, FACEP

Professor of Emergency Medicine and Pediatrics; Section Chief, Pediatric Emergency Medicine; Medical Director, Upstate Poison Control Center, Golisano Children's Hospital, Syracuse, NY

Steven Choi, MD, FAAP

Chief Quality Officer and Associate Dean for Clinical Quality, Yale Medicine/Yale School of Medicine; Vice President, Chief Quality Officer, Yale New Haven Health System, New Haven, CT

Ari Cohen, MD, FAAP

Chief of Pediatric Emergency Medicine, Massachusetts General

Hospital; Instructor in Pediatrics, Harvard Medical School, Boston, MA

Jay D. Fisher, MD, FAAP, FACEP

Clinical Professor of Emergency Medicine and Pediatrics, University of Nevada, Las Vegas School of Medicine, Las Vegas, NV

Marianne Gausche-Hill, MD, FACEP, FAAP, FAEMS

Medical Director, Los Angeles County EMS Agency; Professor of Clinical Emergency Medicine and Pediatrics, David Geffen School of Medicine at UCLA; Clinical Faculty, Harbor-UCLA Medical Center, Department of Emergency Medicine, Los Angeles, CA

Michael J. Gerardi, MD, FAAP, FACEP, President

Associate Professor of Emergency Medicine, Icahn School of Medicine at Mount Sinai; Director, Pediatric Emergency Medicine, Goryeb Children's Hospital, Morristown, NJ

Sandip Godambe, MD, PhD

Chief Quality and Patient Safety Officer, Professor of Pediatrics, Attending Physician of Emergency Medicine, Children's Hospital of The King's Daughters Health System, Norfolk, VA

Ran D. Goldman, MD

Professor, Department of Pediatrics, University of British Columbia; Research Director, Pediatric Emergency Medicine, BC Children's Hospital, Vancouver, BC, Canada

Joseph Habboushe, MD, MBA

Assistant Professor of Emergency Medicine, NYU/Langone and Bellevue Medical Centers, New York, NY; CEO, MD Aware LLC

Alison S. Inaba, MD, FAAP

Pediatric Emergency Medicine

Specialist, Kapiolani Medical Center for Women & Children; Associate Professor of Pediatrics, University of Hawaii John A. Burns School of Medicine, Honolulu, HI

Madeline Matar Joseph, MD, FACEP, FAAP

Professor of Emergency Medicine and Pediatrics, Assistant Chair, Pediatric Emergency Medicine Quality Improvement, Pediatric Emergency Medicine Division, University of Florida College of Medicine-Jacksonville, Jacksonville, FL

Stephanie Kennebeck, MD

Associate Professor, University of Cincinnati Department of Pediatrics, Cincinnati, OH

Anupam Kharbanda, MD, MS

Chief, Critical Care Services Children's Hospitals and Clinics of Minnesota, Minneapolis, MN

Tommy Y. Kim, MD, FAAP, FACEP

Associate Professor of Pediatric Emergency Medicine, University of California Riverside School of Medicine, Riverside Community Hospital, Department of Emergency Medicine, Riverside, CA

Melissa Langan, MD, MHS

Associate Professor of Pediatrics and Emergency Medicine; Fellowship Director, Director of Education, Pediatric Emergency Medicine, Yale University School of Medicine, New Haven, CT

Robert Luten, MD

Professor, Pediatrics and Emergency Medicine, University of Florida, Jacksonville, FL

Garth Meckler, MD, MSHS

Associate Professor of Pediatrics, University of British Columbia;

Division Head, Pediatric Emergency Medicine, BC Children's Hospital, Vancouver, BC, Canada

Joshua Nagler, MD, MHPEd

Assistant Professor of Pediatrics and Emergency Medicine, Harvard Medical School; Associate Division Chief and Fellowship Director, Division of Emergency Medicine, Boston Children's Hospital, Boston, MA

James Naprawa, MD

Attending Physician, Emergency Department USCF Benioff Children's Hospital, Oakland, CA

Joshua Rocker, MD

Associate Chief and Medical Director, Assistant Professor of Pediatrics and Emergency Medicine, Cohen Children's Medical Center of New York, New Hyde Park, NY

Steven Rogers, MD

Associate Professor, University of Connecticut School of Medicine, Attending Emergency Medicine Physician, Connecticut Children's Medical Center, Hartford, CT

Christopher Strother, MD

Associate Professor, Emergency Medicine, Pediatrics, and Medical Education; Director, Pediatric Emergency Medicine; Director, Simulation; Icahn School of Medicine at Mount Sinai, New York, NY

Adam E. Vella, MD, FAAP

Director of Quality Assurance, Pediatric Emergency Medicine, New York-Presbyterian, Weill Cornell, New York, NY

David M. Walker, MD, FACEP, FAAP

Chief, Pediatric Emergency Medicine, Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ

Vincent J. Wang, MD, MHA

Professor of Pediatrics and Emergency Medicine; Division Chief, Pediatric Emergency Medicine, UT Southwestern Medical Center; Director of Emergency Services, Children's Health, Dallas, TX

International Editor

Lara Zibners, MD, FAAP, FACEP, MMed

Honorary Consultant, Paediatric Emergency Medicine, St. Mary's Hospital Imperial College Trust, London, UK; Nonclinical Instructor of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

Pharmacology Editor

Aimee Mishler, PharmD, BCPS

Emergency Medicine Pharmacist, Program Director – PGY2 Emergency Medicine Pharmacy Residency, Maricopa Medical Center, Phoenix, AZ

CME Editor

Brian S. Skrinka, MD, FACEP, FAAP

Clinical Assistant Professor of Emergency Medicine, Oklahoma State University Center for Health Sciences, The Children's Hospital at Saint Francis, Tulsa, OK

APP Liaison

Brittany M. Newberry, PhD, MSN, MPH, APRN, ENP-BC, FNP-BC

Faculty, Emory University School of Nursing, Emergency Nurse Practitioner Program, Atlanta, GA; Nurse Practitioner, Fannin Regional Hospital Emergency Department, Blue Ridge, GA

Case Presentations

An 8-year-old boy presents to the ED after falling at a local playground. His mother, who was with him at the time of the injury, states that he was climbing out of a tree when he slipped and fell. He landed on his outstretched hands and is now complaining of right wrist pain. On examination, he has no open wounds, and he has a normal neurovascular examination, but he has an obvious deformity of his right forearm. The child describes his pain as 7/10. You ponder how best to treat the child's severe pain as quickly as possible...

Your next patient is a 7-year-old boy who is brought in for 1 day of fever and right lower quadrant abdominal pain. His examination is significant for rebound and guarding of his right lower quadrant. The boy rates his pain as 9/10. You order initial laboratory studies. The patient's mother pulls you aside to tell you that her son has had bad experiences with IV placement in the past, and she is very concerned about the associated pain. Meanwhile, one of the nurses tells you that the on-call surgery resident will come to see your patient with possible acute appendicitis, but she will be delayed. The surgeon requested that you defer pain medication until her return to the ED, since pain medication will "ruin" her examination. You consider what to do next...

The last patient of your shift is a 21-day-old infant who presents with a fever to 38.3°C (100.9°F). The patient has had upper respiratory symptoms for 1 day. On examination, she has some upper respiratory congestion but is otherwise well appearing. You order blood, urine, and cerebrospinal fluid studies to conduct a full evaluation for occult infection. The parents express apprehension about the lumbar puncture, but eventually agree to the procedure. You begin to think about how best to treat your young patient's procedural pain while maximizing the likelihood of a successful lumbar puncture...

Introduction

Pain, as defined by the International Association for the Study of Pain, is "an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage."¹ The quality and location of pain may alert the emergency clinician to the presence of disease processes. Additionally, pain is a frequent—but often preventable—side effect of many of the diagnostic studies and treatments performed in the emergency department (ED), ranging from simple intravenous (IV) line placement to a complex fracture reduction.

For a variety of reasons, adequate treatment of pain can be one of the most challenging aspects of emergency medicine practice. First, pain is subjective. Despite the development of sophisticated pain scales, patient self-report is the best source of pain measurement in communicative patients. This can

often lead to confusion when patient pain reports do not match emergency clinician expectations. Second, the pressures resulting from the volume of critical patients seen in the ED can make optimum pain management a seemingly impossible goal and lower its priority. Third, young patients' developmental levels can make quantifying and qualifying their pain difficult and can reduce their ability to advocate for the treatment of their pain. Fourth, unfounded concerns from both emergency clinicians and consultants regarding "masking" pain and interfering with accurate diagnoses may lead emergency clinicians to undertreat pain. Finally, the concerns emergency clinicians and patients' families have regarding side effects and the unclear potential for addiction may make emergency clinicians reluctant to use certain effective pain medications.

Despite these barriers, there are compelling reasons to treat pain in the ED. The relief of suffering is one of the fundamental goals of medicine. The adequate treatment of pain increases patient satisfaction.² Despite long-standing myths, all patients (including neonates) feel pain,³ and there is convincing evidence that exposing young patients to painful stimuli can have both short-term and long-term negative consequences.⁴⁻⁷

Pain has been traditionally undertreated in all populations, but this is especially true in pediatric patients. The purpose of this issue of *Pediatric Emergency Medicine Practice* is to help emergency clinicians recognize pain in children, develop strategies to successfully manage pain in pediatric patients, and address specific areas where controversy in pain management exists.

Critical Appraisal of the Literature

A literature search was performed in Ovid MEDLINE[®] and PubMed using multiple combinations of the search terms *pain, pain management, analgesia, adverse events, side effects, children, pediatric, and emergency department*. The Cochrane Database of Systematic Reviews was also consulted. Articles relevant to pediatric pain management were selected, reviewed, and included in the references, as were citations that appeared in review articles, clinical practice guidelines, and policy statements. Articles were chosen for inclusion if they were published after 1995; however, important articles published before this date were included for completeness and historical perspective. Over 400 articles were reviewed, 201 of which were chosen for inclusion in this review.

For many years, there was a paucity of data on acute pain management in a few small, often contradictory, studies. Recently, the Cochrane Library has published more actionable recommendations, but there is still a lack of multicenter randomized controlled trials. In addition, there are few data on the

long-term effects of exposure of pediatric patients to pain in the ED.

The History of Pain Treatment

Despite the clinical and ethical imperative for clinicians to treat pain and reduce patient suffering, pain in both adult and pediatric patients has traditionally been undertreated.⁸⁻¹¹ Underutilization of pain medication has been particularly pronounced in children, since, historically, it has been thought that children "...seldom need medication for relief of pain. They tolerate discomfort well."¹² This has frequently led to children either not receiving analgesics or receiving insufficient doses of analgesics. In the past, many believed that infants did not experience pain; historically, cardiac surgeries have even been performed on neonates without analgesia.¹³ Numerous studies in the 1980s quantitatively demonstrated a pronounced lower usage of analgesics for definitively painful conditions in children versus adults.^{8,14} A study published in 1990 documented this phenomenon in the ED, showing that children received analgesics significantly less frequently than adults (28% vs 60%, $P < .001$) when presenting with painful conditions.⁹

Despite improved understanding of pediatric pain as well as the introduction of newer, safer agents, the use of sedation and analgesia remains highly variable across patients and hospitals.¹⁵⁻¹⁷ However, as a greater understanding of the negative consequences of untreated pain has developed, many in the medical community began to refute the misperceptions surrounding pediatric pain,¹⁸ and a concerted effort to make the ED an "ouchless" place for children began to develop.² Today, a variety of modalities, both pharmacologic and non-pharmacologic, are available for pediatric patients to help minimize the pain and anxiety associated with an ED visit.

Physiology of Pain

The physiology of the pain response is complex and multifactorial. The traditional model of pain transmission is "bottom-up," wherein a specific level of painful stimulus causes a proportional signal from the periphery, through the spinal cord to the brain, and leads to a specific, predictable level of pain. New insights into the physiology of pain, however, have led scientists to reconsider this model. A new, "top-down" conception of pain has developed, in which painful stimuli are thought to be subject to modification in both the spinal cord and the brain.¹⁹ The patient's age and temperament, past experience, personal and familial beliefs, culture, and genetics are a few of the factors that may alter the final perception of a single painful stimulus. Pain pathways also demonstrate significant plasticity. Unlike other

processes, exposure to painful stimuli results in upregulation of pain pathways, potentially leading to pain hypersensitivity,²⁰ with these effects being greatest early in life.²¹

In both infants and children, painful stimuli can result in long-term harmful effects. Full-term infants who had circumcisions in the immediate neonatal period have been shown to have significantly greater pain response to vaccinations at 4 and 6 months than infants who were not circumcised.²² One study of pediatric cancer patients receiving a lumbar puncture (LP) examined the relationship between procedural pain and past experience. It found that, despite all patients receiving the same analgesia during the study LP, patients who had received fentanyl during a previous LP had lower pain scores than those who had received placebo during a previous LP.²³ Another study found that the number of invasive procedures performed during a hospital stay was directly associated with ongoing post-traumatic stress responses 6 weeks after discharge, and increased medical fears 6 weeks and 6 months after discharge.²⁴ Psychological outcomes of painful procedures extend into adulthood, with people who experienced more medical fear and pain as children having more medical fear as adults.²⁵

Prehospital Care

Prehospital care traditionally focuses on the stabilization of potential life-threatening issues; however, prehospital pharmacologic pain management and nonpharmacologic pain management (eg, with ice packs, immobilization of fractures, elevation of extremities, and distraction techniques) have been recognized and recommended by both the National Association of EMS (emergency medical services) Physicians and the American Academy of Pediatrics.^{26,27} Additionally, guidelines for the care of pain in the prehospital setting have been disseminated²⁸ and implemented at the statewide level.²⁹ Despite these recommendations, pediatric pain is frequently underrecognized and undertreated in the prehospital and ED settings.^{27,30-33}

Pain is a common prehospital symptom, with 37% to 69% of children estimated to experience acute pain and 48% to 67% of these children classified as having "intense to severe" pain.^{34,35} One study found that most children (78%) receive prehospital analgesia either at home or from EMS providers; however, the majority of children (65%) with moderate to severe pain do not receive any prehospital pharmacologic analgesia.³⁶ Another study demonstrated that, in the prehospital setting, children and adolescents are much less likely than adults to have a pain score documented (4% vs 67%), and they are also less likely to receive an analgesic intervention.³⁷ Canadian paramedics report being similarly

less likely to provide analgesics to children versus adults.³⁸ Pediatric trauma patients have also been identified as lacking adequate prehospital documentation of pain assessments and interventions.³⁹ EMS providers cite the inability to assess pain in children and adolescents and limited clinical experience with children as the most common reasons for withholding analgesia.^{37,38} Pain documentation and treatment in the prehospital setting has remained suboptimal even after implementation of updated pain management protocols.^{31,32}

Numerous studies of adult and pediatric patients have demonstrated safe administration of opioids in the prehospital setting.⁴⁰⁻⁴⁵ Intranasal fentanyl has the advantages of rapid administration and efficacy comparable to IV administration; its use is supported in published guidelines.^{4,28,45} The use of intranasal ketamine for prehospital analgesia has been described, but has not been widely studied or implemented to date.⁴⁶⁻⁴⁸

Emergency Department Evaluation

The Joint Commission (www.jointcommission.org) mandates pain assessment for all patients.⁴⁹ Pain should be assessed for all patients upon initial presentation to the ED and reassessed during the visit. Early and frequent pain assessment encourages and assists clinicians in the recognition and treatment of pain.


Pain Scales

Pain may be quantified by patient self-report, behavioral assessment, or physiologic indicators. The gold standard and most desirable method for pain assessment, when obtainable, is based upon self-report of pain by the patient. Pain assessment scales for self-reporting of pain exist for children as young as 3 years of age. These include the Faces Pain Scale-Revised (FPS-R) (see Figure 1), the color analog scale (CAS), and the 11-point numeric rating

scale (NRS-11). For younger children or for children unable to use self-report pain scales, behavioral scales such as the Faces, Legs, Activity, Cry, and Consolability (FLACC) Scale have been validated in the pediatric ED setting⁵⁰ (see Table 1) and may be utilized in conjunction with the child's history and physical examination. Behavioral scales may also be used in conjunction with self-reporting scales in preschool-aged children who may not be able to fully understand and use a self-report pain scale.⁵¹ The NRS-11, FPS-R, and CAS are strongly recommended for self-report of acute pain.⁵² The evidence for these 3 tools is not as strong for the measurement of postoperative pain, and no specific self-report tool can be recommended for pain assessment in children aged < 6 years.⁵² A summary of the recommended pain scales for the intended age groups is listed in Table 2, page 5.

Regardless of which pain scale is chosen, the absolute value of the pain score is not as important as the change in the score for each individual child. Pain is an individual experience, and the perception of pain varies between individuals. Noting changes in pain scores can help emergency clinicians gauge the effectiveness of interventions.

Figure 1. Faces Pain Scale - Revised



Faces Pain Scale - Revised © 2001, International Association for the Study of Pain.

Hicks CL, von Baeyer CL, Spafford P, van Korlaar I, Goodenough B. Faces Pain Scale-Revised: Toward a Common Metric in Pediatric Pain Measurement. *Pain*. 2001; 93:173-183.

This Faces Pain Scale-Revised (www.iasp-pain.org/fpsr) has been reproduced with permission of the International Association for the Study of Pain® (IASP). The figure may NOT be reproduced for any other purpose without permission.

Table 1. Face, Legs, Activity, Cry, Consolability Scale

Categories	Scoring		
	0	1	2
Face	No particular expression or smile	Occasional grimace or frown, withdrawn, disinterested	Frequent to constant frown, clenched jaw, quivering chin
Legs	Normal position or relaxed	Uneasy, restless, tense	Kicking, or legs drawn up
Activity	Lies quietly, normal position, moves easily	Squirming, shifting back and forth, tense	Arched, rigid, or jerking
Cry	No cry (awake or asleep)	Moans or whimpers, occasional complaint	Cries steadily, screams or sobs, frequent complaints
Consolability	Content, relaxed	Reassured by occasional touching, hugging, or being talked to, distractible	Difficult to console or comfort

Each of the 5 categories (F) Face; (L) Legs; (A) Activity; (C) Cry; (C) Consolability is scored from 0-2, which results in a total score between 0 and 10.

© 2002 The Regents of the University of Michigan. Used with permission.

Though pain scales all measure the same phenomenon, they may not be interchangeable. One study found little agreement between 4 pain scales (visual analog scale, CAS, Wong-Baker FACES® Pain Rating Scale, and verbal numeric scale) in a pediatric ED.⁵³ Another study correlated pain scores on the FPS-R and CAS scales to perceptions of no pain, mild pain, moderate pain, and severe pain. On the FPS-R, they found that “no pain” correlated to scores of 0 and 2, “mild pain” to 4, “moderate pain” to 6, and “severe pain” to 8 and 10. For the CAS, scores of 0 to 1 correlated to “no pain,” 1.25 to 2.75 to “mild pain,” 3 to 5.75 to “moderate pain,” and 6 to 10 to “severe pain.”⁵⁴ Since different scales may provide different results, reassessment of pediatric pain should be completed using the same scale throughout the child’s ED visit.

Treatment

Nonpharmacologic Management

When pain is recognized, nonpharmacologic pain management techniques should begin before medications are administered. The use of a multidisciplinary approach to pain management in pediatric patients has been shown to decrease pain scores, improve parental satisfaction, improve compliance, and decrease hospitalization rates for pain associated with conditions such as sickle cell disease and pediatric cancer.⁵⁵⁻⁵⁷ Despite the report of pain by pediatric patients, nurses in multiple studies did not commonly administer prescribed pain medications to pediatric patients,^{58,59} and the nurses often perceived that pediatric patients were overreporting their pain,⁶⁰ thereby decreasing the efficacy of pharmacologic pain regimens. It is therefore important to have an approach to pain management that does not rely only on medica-

tions, but instead incorporates multiple evidence-based approaches to the treatment of pain.

There is evidence that nonpharmacologic techniques can reduce patient procedural pain. A 2018 Cochrane review found that cognitive and behavioral interventions decreased needle-related procedure pain in patients aged 2 to 19 years. Although the evidence is not strong, techniques such as distraction and hypnosis may reduce procedural pain and distress.⁶¹

Distraction, one of the most well-established nonpharmacologic methods of procedural pain management, can be used in any setting. Many studies of distraction involve showing children cartoons or movies.⁶¹ Music, computer games, blowing bubbles, and toys and games are alternate methods of distraction. With the ubiquity of smart phones, virtually all parents have a means of distraction in their possession. Age-appropriate distraction techniques include rattles and mirrors for infants; bubbles and blocks for toddlers; puzzles, toys, and stickers for preschoolers; modeling clay, music, and electronic devices for school-aged children; and movies and video games for adolescents.⁶²

While discussing a procedure before its performance has not been shown to reduce procedural pain by itself, it has been combined with other techniques to reduce procedural distress.⁶¹ Care must be taken before and during procedures to avoid focusing on the upcoming pain; instead, focus on distraction techniques. As part of combined interventions, deep breathing, relaxation techniques (eg, stress balls), and visualization techniques (eg, picturing yourself on vacation) may also reduce procedural distress.⁶¹

In younger patients, interventions such as nonnutritive sucking and swaddling have also been shown to reduce pain.⁶³ Breastfeeding has also been demonstrat-

Table 2. Summary of Recommended Pain Scales Used for Children

Name of Scale	Recommended Age Group	Notes
Faces, Legs, Activity, Cry, Consolability (FLACC) Scale	2 months–4 years	<ul style="list-style-type: none"> Initially developed to evaluate postoperative pain Some evidence to support use in acute pain and procedural pain May not distinguish pain from anxiety
Faces Pain Scale-Revised (FPS-R)	4 years–12 years	<ul style="list-style-type: none"> Quick and simple to use Minimal instruction required Translated into > 35 languages Available free of charge Strongest evidence for use in children aged > 7 years
Color analog scale (CAS)	5 years–16 years	<ul style="list-style-type: none"> 10-cm vertical scale with increasing gradations of color and width to signify increasing pain Severity of pain measured in 0.25 cm increments Strongest evidence for use in children aged > 7 years
11-point numeric rating scale (NRS-11)	4 years–18 years	<ul style="list-style-type: none"> Initially developed and studied for use in adults Numerical scale from 0–10, can be administered verbally Mild pain, 1–3; moderate pain, 4–6; severe pain, 7–10 Best evidence in patients aged ≥ 6 years

ed to reduce procedural pain in infants.⁶⁴ All of these nonpharmacological techniques can reduce pain and increase parental satisfaction in an efficient manner.

Topical Anesthesia

There are multiple options for topical anesthesia that are both safe and effective for use in the pediatric population. Topical anesthetics can decrease pain, increase cooperation in pediatric patients, and improve procedure success.⁶⁵ Topical anesthetics may be used either alone or in combination with other agents to reduce the need for systemic medications.⁶⁶

EMLA®

EMLA® cream (with each gram of cream containing 25 mg lidocaine and 25 mg prilocaine as an oil-and-water emulsion) is commonly used to anesthetize the skin prior to invasive local procedures in children. It is typically used only on intact skin, to minimize systemic absorption,⁶⁷ although a nonsystematic review of studies using EMLA® on lacerations found that it was successful, without significant side effects.⁶⁸ EMLA® has been used clinically for over 25 years, and numerous studies have shown its effectiveness; a meta-analysis of 20 studies showed it to have a significant effect on both venipuncture pain and IV insertion pain.^{69,70} The major disadvantage of EMLA® is its long onset of action (45 to 60 minutes to achieve the desired effect). A potential complication for neonates receiving topical EMLA® cream is methemoglobinemia from the metabolites of prilocaine secondary to low levels of methemoglobin reductase.^{71,72} The incidence is highest in patients aged < 3 months and is related to the duration of skin application. EMLA® does not affect procedural success in IV cannulation.⁷³

LMX® and Topical Tetracaine

LMX® is 4% lidocaine and is available in both a gel and cream. The most commonly used formulation of LMX® is the cream. The gel formulation of high-concentration lidocaine, LMX®, is similar to EMLA®. It is used topically to anesthetize intact skin, and its effects are seen more quickly than with EMLA®, sometimes as quickly as 20 minutes after application. Two studies that assessed pain with IV placement have found equivalent pain relief with a 30-minute application of LMX® or a 60-minute application of EMLA®, although these trials did not have a placebo control.^{74,75} Topical tetracaine is also available outside the United States for local anesthesia prior to venipuncture, providing similar anesthesia to liposomal lidocaine.⁷⁶

Needle-Free Lidocaine

Needle-free, local jet-injection of lidocaine can be used prior to IV catheter placement in children to reduce pain and facilitate patient cooperation. The sin-

gle-use system uses a carbon dioxide gas cartridge under high pressure to deliver 1% buffered lidocaine through a micro-orifice into the subcutaneous layers of the skin. It provides almost immediate anesthesia and has been shown to be more effective than placebo, vapocoolant spray, and EMLA® for IV placement.⁷⁷⁻⁷⁹ It also does not affect the rate of IV placement success.⁸⁰ Another study, however, showed no difference between jet-injection of lidocaine and jet-injection of placebo, although both were superior to controls receiving no anesthesia with IV placement.⁸¹ Prior to LP, jet-injection of lidocaine has been shown to be superior to jet-injection of placebo.⁸²

LET

Lidocaine, epinephrine, and tetracaine (LET) is a topical anesthetic that can supplement or replace local infiltration of lidocaine for laceration repair. Use of LET can facilitate cooperation and decrease anxiety because the topical application of the medications avoids needles. LET has been shown to be effective for laceration repair, with few side effects.^{72,83} LET has an equal anesthetic effect compared to injected lidocaine, with less pain on application.⁸⁴ Additionally, application of LET reduces the pain associated with lidocaine injection, should it subsequently become necessary.⁸⁵ Placement of LET on lacerations by nurses in triage has been shown to decrease treatment time for children presenting with lacerations in need of repair.⁸⁶

Vapocoolant

Ethyl chloride spray and other products (eg, Pain Erase®) are vapocoolant sprays used for cryoanalgesia for IV placement as well as incision and drainage procedures for pediatric patients. Its use has decreased with the advent of other forms of topical analgesia, but it is still commonly used in some settings. A Cochrane review found moderate evidence that use of vapocoolant immediately before IV cannulation reduced procedural pain,⁸⁷ although the clinical significance of the small improvement in pain observed is unclear.⁸⁸ In one study, vapocoolant was found to be inferior to EMLA® for the relief of IV catheterization-associated pain.⁸⁹

Local Anesthesia

Local anesthetics can be delivered via needle into the area of a wound (or the area surrounding) or the area where a procedure is to take place. Lidocaine is the most commonly used agent. It has a rapid onset of action, with a duration of action of 30 to 60 minutes (without epinephrine). Commonly, epinephrine is used in combination with lidocaine, providing vasoconstriction, decreased bleeding, and delayed systemic absorption of lidocaine. The delayed absorption can increase the duration of anesthesia the produced to between 160 to 240 minutes. Maxi-

mum recommended doses of lidocaine are 4.5 mg/kg without epinephrine and 7 mg/kg with epinephrine.⁹⁰⁻⁹² Dysrhythmias, seizures, and cardiovascular collapse have been reported rarely with the use of local anesthetic agents, typically with supratherapeutic dosing.⁹²

Because lidocaine has a low pH, studies have shown that using 9 mL of 1% lidocaine and combining it with 1 mL of 8.4% sodium bicarbonate (9:1 ratio) can decrease the burning that is often associated with its administration.⁹³ A Cochrane review of 23 studies showed that adjusting the pH of lidocaine both decreased observed pain scores and improved patient satisfaction.⁹⁴ Using 25-gauge or smaller needles, infiltrating slowly, and stimulating the skin just proximal to the site of injection can decrease pain sensation.⁹⁵ Additionally, in a systematic review and meta-analysis, warming lidocaine prior to injection was also shown to improve pain scores upon lidocaine administration.⁹⁶

Other agents, such as mepivacaine, bupivacaine, prilocaine, and etidocaine can also be useful if administered before painful procedures because of their longer duration of action compared to lidocaine. These anesthetics are sometimes used in combination with lidocaine to prolong the duration of anesthesia, but many agents can be used singularly. Some disadvantages of these medications include a longer duration until onset of pain relief and more frequent reports of local anesthetic systemic toxicity⁹² compared to lidocaine. The onset and duration of action of several common local anesthetics is listed in **Table 3**.

Regional Anesthesia

Regional anesthesia and peripheral nerve blocks may also be used to address pain associated with fractures and laceration repair in the ED. Regional anesthesia involves the injection of a local anesthetic in the area of a nerve in order to provide anesthesia to a particular nerve distribution. Compared to local infiltration, advantages of regional anesthesia include reduced pain, less anesthetic use, lower risk for systemic toxicity, and less tissue distortion.⁹⁷ Disadvantages include the need for a high degree of patient cooperation, a risk of systemic toxicity due

Table 3. Onset and Duration of Action of Common Local Injectable Anesthetic Medications

Medication	Onset (min)	Duration (min)
Lidocaine	1-3	30-60
Lidocaine with epinephrine	1-4	160-240
Mepivacaine	4-7	120-180
Bupivacaine	5-10	120-360
Prilocaine	1-2	60-120

www.ebmedicine.net

to inadvertent intravascular injection, and a small risk of peripheral nerve damage.⁹⁷ Typical anesthetics used for regional anesthesia and nerve blocks include lidocaine, bupivacaine, and ropivacaine.

There are several indications for the use of peripheral nerve blocks in the ED. Digital blocks provide excellent anesthesia for nail bed repairs, laceration repairs, and foreign body removal from fingers and toes. Femoral nerve blocks can be used for immediate relief of femur fracture pain. Axillary blocks can be used for anesthesia during forearm fracture reductions. Facial nerve blocks, including infraorbital, supraorbital, and mental nerve blocks, are often used for regional anesthesia for facial laceration repair. The addition of ultrasound guidance has been shown to be more effective than traditional landmark techniques for nerve blocks of the extremities.⁹⁸

Systemic Agents

Nonopioid Analgesics

Acetaminophen

Acetaminophen (paracetamol, APAP) is the most widely used analgesic and antipyretic in children. Its exact mechanism of action is unknown. Unlike nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen does not have anti-inflammatory or antiplatelet properties.

While acetaminophen has an excellent safety profile overall, a risk for severe hepatotoxicity and necrosis in patients receiving supratherapeutic doses of acetaminophen exists, especially in patients receiving repeated dosing.^{99,100} Families frequently give incorrect doses of acetaminophen at home, so it is important to provide explicit, appropriate dosing instructions.^{101,102} Acetaminophen is typically administered orally or rectally, with maximum daily dosing varying by weight or age.¹⁰³ The oral dose of acetaminophen is 10 to 15 mg/kg, which may be repeated every 4 to 6 hours. The usual recommended rectal dosage of acetaminophen is 10 to 20 mg/kg/dose.¹⁰⁴ Given its variable bioavailability, caution should be used when administering rectal acetaminophen, especially in children in a catabolic state due to their underlying illness.¹⁰⁵ There is also an IV formulation of acetaminophen. Although its current use is limited by its expense, it has been used successfully in a pediatric ED setting.¹⁰⁶ (See **Table 4**, page 8.)

Nonsteroidal Anti-Inflammatory Drugs

NSAIDs have both analgesic and anti-inflammatory effects and are often used in the treatment of mild to moderate pain for pediatric patients in the ED.

Ibuprofen

Ibuprofen is the most frequently administered NSAID for pediatric patients. Although an IV formulation of

ibuprofen exists (eg, to hasten patent ductus arteriosus closure in neonates), only the oral formulation is FDA-approved for the treatment of pain in children.¹⁰⁷ Dosing of ibuprofen is 10 mg/kg, with a maximum dose of 400 mg, not to exceed 40 mg/kg every 24 hours. (See Table 4.) The risk of harm from overdose is less with ibuprofen than acetaminophen, although significant acidosis, renal failure, coma, and death have been reported from massive (> 400 mg/kg) overdoses of ibuprofen.^{108,109}

Several meta-analyses have compared the efficacy and safety profile of acetaminophen and ibuprofen in children. In all meta-analyses, the safety and side-effect profiles of acetaminophen and NSAIDs were similar, with fewer adverse events than with opioids.¹¹⁰⁻¹¹³ Perrott et al concluded that both agents had similar efficacy against pain,¹¹⁰ while Pierce and Voss found that ibuprofen may be more efficacious in treating pediatric pain.¹¹² Similarly, Le May et al found ibuprofen to be superior to acetaminophen in the treatment of mild to moderate musculoskeletal pain.¹¹⁴ A Cochrane review of medications for pain in otitis media found insufficient evidence of a difference between ibuprofen and acetaminophen.¹¹⁵ Additionally, a recent multicenter prospective trial found no difference in asthma exacerbation frequency in children with mild asthma subsequent to using acetaminophen or ibuprofen.¹¹⁶

Other NSAIDs

Other NSAIDs have also been used in pediatric patients. Aspirin was the first NSAID developed for clinical use; however, its association with Reye syndrome has led to its discontinuation for use in children with pain or fever.¹¹⁷ Naproxen has similar efficacy to ibuprofen but has the advantage of a longer half-life.¹¹⁸ It has not been studied for use

in infants. Ketorolac is the only NSAID with an IV formulation approved for analgesia in pediatric patients. While it has been associated with cases of renal failure¹¹⁹ and gastrointestinal bleeding¹²⁰ in pediatric patients, short courses (< 5 days) of ketorolac are safe in patients without baseline renal or gastrointestinal issues.¹²¹ A tablet form of ketorolac exists, but there have been few studies regarding its use in children. Indomethacin has not been studied in patients aged < 14 years,¹²² but it has been used in patients with rheumatic diseases. Dosing of nonopioid analgesics is summarized in Table 4.

Side Effects of NSAIDs

With typical usage, NSAIDs are well tolerated in children, although side effects do exist. Case reports demonstrate NSAID-associated renal failure in pediatric patients using NSAIDs for short periods, although all cases were self-limited with drug discontinuation.¹²³ Despite a high prevalence of NSAID-induced bronchospasm in adults, at least 1 randomized controlled trial showed a reduced risk of outpatient visits for asthma in pediatric patients with a history of asthma and an acute febrile illness who were prescribed ibuprofen versus those given acetaminophen.¹²⁴ Two meta-analyses showed no evidence of a significant difference in postsurgical bleeding in tonsillectomy patients receiving NSAIDs perioperatively versus other tonsillectomy patients.^{125,126} A randomized double-blind office-based study enrolling over 80,000 patients showed no difference in rates of hospitalization for gastrointestinal bleeding, renal failure, or anaphylaxis in patients prescribed ibuprofen versus those prescribed acetaminophen.¹²⁷

Table 4. Dosing of Nonopioid Analgesics

Medication	Route	Dosing	Frequency
Acetaminophen	Oral	10-15 mg/kg/dose (max 650 mg), infants and children	Every 4-6 hr, infants and children
	Rectal	10-20 mg/kg/dose (max 650 mg)	Children, every 6 hr Neonates, every 12 hr
	Intravenous	<ul style="list-style-type: none"> Age < 2 yr: 7.5–15 mg/kg/dose (max 60 mg/kg/day) Age ≥ 2 years, weight < 50 kg: 15 mg/kg (max 75 mg/kg/day or 3750 mg) Age ≥ 2 years, weight ≥ 50 kg: 1 g (max 4 g/day) 	Every 6 hr
Ibuprofen	Oral	10 mg/kg/dose (max 400 mg)	Every 6 hr
Naproxen	Oral	5-6 mg/kg/dose (max 500 mg)	Every 12 hr
Ketorolac	Intravenous	0.5 mg/kg/dose (max 30 mg)	Every 6 hr for ≤ 5 days

Neonate: aged < 1 month

Infant: aged < 12 months

Child: aged 1 to 18 years

www.ebmedicine.net

Opioid Analgesics

Opioids are the mainstays of treatment of moderate to severe pain in children in the ED. While opioids have a significant side-effect profile that must be recognized, these side effects can be minimized when opioids are used appropriately. For severe pain, opioids should be given concurrently with NSAIDs and/or acetaminophen, when possible. For mild to moderate pain, opioids should be given only for breakthrough pain after NSAIDs and/or acetaminophen have been administered. Dosing of opioid analgesics is summarized in **Table 5**.

Codeine

Codeine, once a mainstay in pain management, is now recognized as a high-risk medication and its use has been greatly restricted in children in the United States,¹²⁸ Canada,¹²⁹ and Europe.¹³⁰ Codeine itself has an extremely weak affinity for opioid receptors. Its analgesic effect comes from the approximately 10% of ingested codeine that is metabolized into morphine by the CYP2D6 enzyme in the liver.¹³¹ However, there are a number of CYP2D6 genetic polymorphisms that affect its rate of catalysis. In North America, 7% to 10% of white people have a polymorphism of CYP2D6, which causes the enzyme to have little function; thus, these patients receive virtually no analgesic effect from codeine.¹³² Conversely, 1% to 7% of white people and > 25% of Ethiopians, among others, have a polymorphism of CYP2D6 that causes very fast metabolism of codeine, creating a high potential for toxicity and death;¹³³ this polymorphism has been linked to multiple fatalities.^{134,135} Additionally, ibuprofen has been shown to provide greater pain relief than codeine in pediatric patients with acute musculoskeletal injuries,¹³⁶ and the addition of codeine to ibuprofen has not been shown to provide additional benefit in pediatric patients with acute limb injuries.¹³⁷

With better alternatives available, use of codeine for analgesia should be avoided.

Tramadol

Tramadol is a prodrug, that, similar to codeine, is metabolized by the CYP2D6 enzyme into its active form, desmetramadol. Like codeine, depending on an individual's CYP2D6 polymorphism, tramadol may provide either minimal analgesia or toxic effects even when given at previously recommended doses.¹³⁸ Tramadol is not recommended for children aged < 12 years. In all ages, it is not a first-line medication, and should be used selectively, if at all.¹²⁸

Oxycodone

Oxycodone is frequently used and prescribed in pediatric EDs in the United States.¹³⁹ Unlike codeine, it does not need to be metabolized to an active form. Caution should be used in dosing oxycodone in patients with renal failure, since they may develop toxic levels of its metabolites.¹⁴⁰

Hydrocodone

Hydrocodone is an oral opioid with similar potency to oxycodone; however, the most common formulations are combined with acetaminophen and ibuprofen, which may limit its utility.

Morphine

Morphine is a mainstay of treatment of severe pain in pediatric ED patients. It is metabolized in the liver to inactive morphine-3-glucuronide and active morphine-6-glucuronide, both of which are excreted by the kidneys. Caution should be used in giving morphine to patients in renal failure, since the active toxic metabolite can accumulate.¹⁴¹ Morphine is metabolized predominantly into the active metabolite in infants. It has both a smaller volume of distribution and a longer clearance time in these patients;


Table 5. Dosing of Opioid Analgesics

Medication	Route	Dosing	Frequency
Oxycodone	Oral	0.05–0.2 mg/kg/dose (initial max 5–10 mg)	Every 4–6 hr
Hydrocodone	Oral	0.1–0.2 mg/kg/dose (max 10 mg) ^a	Every 4–6 hr
Morphine	Intravenous	0.05–0.1 mg/kg/dose (initial max 4 mg, titrate as needed) ^b	Every 2–4 hr
	Oral	0.2–0.5 mg/kg/dose (max 15–30 mg)	Every 4 hr
Hydromorphone	Intravenous	0.01–0.015 mg/kg/dose (max 0.2–0.6 mg)	Every 3–6 hr (infants and children weighing < 50 kg) or every 2–4 hr (children/adolescents > 50 kg)
	Oral	0.03–0.06 mg/kg/dose (max 1–2 mg)	Every 4–6 hr
Fentanyl	Intravenous	0.5–1 mcg/kg/dose (max 50 mcg)	May repeat every 30–60 min
	Intranasal	1–2 mcg/kg/dose (max 100 mcg)	Additional 0.3–0.5 mcg/kg every 5 min, if needed

^aUsually paired with acetaminophen; dosing hydrocodone component.

^bInitial dosage for neonates, 0.025 mg/kg/dose

Clinical Pathway for the Management of Pain in Pediatric Patients



Abbreviations: CAS, color analog scale; FLACC, Faces, Legs, Activity, Cry, Consolability Scale; FPS-R, Faces Pain Scale-Revised; IV, intravenous.

Class of Evidence Definitions

Each action in the clinical pathways section of *Pediatric Emergency Medicine Practice* receives a score based on the following definitions.

Class I

- Always acceptable, safe
- Definitely useful
- Proven in both efficacy and effectiveness

Level of Evidence:

- One or more large prospective studies are present (with rare exceptions)
- High-quality meta-analyses
- Study results consistently positive and compelling

Class II

- Safe, acceptable
- Probably useful

Level of Evidence:

- Generally higher levels of evidence
- Nonrandomized or retrospective studies: historic, cohort, or case control studies
- Less robust randomized controlled trials
- Results consistently positive

Class III

- May be acceptable
- Possibly useful
- Considered optional or alternative treatments

Level of Evidence:

- Generally lower or intermediate levels of evidence
- Case series, animal studies, consensus panels
- Occasionally positive results

Indeterminate

- Continuing area of research
- No recommendations until further research

Level of Evidence:

- Evidence not available
- Higher studies in progress
- Results inconsistent, contradictory
- Results not compelling

This clinical pathway is intended to supplement, rather than substitute for, professional judgment and may be changed depending upon a patient's individual needs. Failure to comply with this pathway does not represent a breach of the standard of care.

Copyright © 2019 EB Medicine. www.ebmedicine.net. No part of this publication may be reproduced in any format without written consent of EB Medicine.

therefore, the dosing should be reduced.^{142,143} Morphine is often given intravenously; an oral formulation is available, but it has not been shown to be superior to ibuprofen for musculoskeletal injuries, and it has more frequent side effects.¹⁴⁴

Hydromorphone

Hydromorphone is a synthetic opioid with an onset and duration similar to morphine. It is thought to have less associated nausea and pruritus than morphine; however, the increased euphoria associated with hydromorphone makes this a potential drug of abuse.

Fentanyl

Fentanyl is a synthetic opioid with rapid onset and offset, making it an excellent agent for immediate pain treatment. It is highly lipid soluble and, therefore, rapidly penetrates the central nervous system. It then diffuses from the central nervous system into the systemic circulation, allowing for rapid termination of effect. The peak effect for IV fentanyl is 3 to 5 minutes, with a duration of effect of 30 to 60 minutes.¹³¹

There are a number of techniques for administration of fentanyl, several of which offer particular advantages in the ED setting. Intranasal fentanyl has been successfully used for pain relief in the pediatric ED¹⁴⁵ and in the prehospital setting.⁴⁵ A randomized controlled trial found that intranasal fentanyl had similar efficacy and time to onset as IV morphine in treating pediatric patients with fracture pain.¹⁴⁵ This study did not account for time to administration, which would presumably favor intranasal fentanyl, since there is no need for IV placement.

Using an atomizer and maximizing drug concentration are important to optimizing drug delivery of intranasal fentanyl,¹⁴⁶ although in one study, similar analgesia was achieved with either standard-IV-concentration or high-concentration intranasal fentanyl.¹⁴⁷ Another study showed that use of intranasal fentanyl for all pediatric patients presenting with pain from any cause led to decreased wait time to pain medication administration by approximately 30 minutes, compared to IV morphine, although the study did not assess time to pain relief.¹⁴⁸ Given the limited number of studies on the use of intranasal fentanyl, a 2014 Cochrane review could not reach a definitive conclusion regarding the efficacy of intranasal fentanyl when compared to morphine.¹⁴⁹

Nebulized fentanyl has also been administered to pediatric patients in the ED setting. Two small pediatric studies also found comparable or improved analgesia with nebulized fentanyl compared to IV opioids.^{150,151}

Side Effects of Opioids

Respiratory depression is the most significant potential side effect of opioids. Binding of opioids to receptors in the medullary respiratory center can lead to hypoventilation and apnea. Cardiopulmonary monitoring of all patients receiving IV opioids is, therefore, mandatory, to obviate this potentially fatal complication. The peak effect of an IV dose of morphine is 10 to 20 minutes, and 3 to 5 minutes after an IV dose of fentanyl.¹⁴¹ Hypotension after administration of morphine is uncommon, but it can occur secondary to histamine release. Gastrointestinal side effects of opioids include ileus, constipation, and vomiting. Severe pruritus is occasionally a side effect of morphine. Chest-wall rigidity is a known complication of fentanyl, and it is associated with higher dosing and rapid IV administration of the medication.

Management of Opioid Overdose

In the event of accidental, recreational, or iatrogenic opioid overdose in children, naloxone reverses opioid effects with minimal side effects. Recommended dosing of naloxone for children is 0.1 mg/kg IV, with a 2-mg maximum dose. This dosing is higher than what is recommended for adults, as children are rarely chronic opioid users and will not experience withdrawal symptoms. Adolescents suspected of chronic opioid use should receive naloxone at adult doses. Higher doses of naloxone, up to 10 mg, may be necessary in cases of toxicity with synthetic opioids, such as fentanyl and its derivatives.

Special Circumstances

Abdominal Pain

Traditional surgical teaching about abdominal pain held that analgesia should be deferred in patients with acute abdominal pain so that clinical progression could be monitored. This practice is now obsolete, as deferring analgesia causes significant harm without any evidence of benefit. Kim et al were the first to examine the question of the use of pain medicine and the masking of clinically significant abdominal symptoms by comparing pain scores, examination findings, and the time to clinical decision-making in children aged > 5 years presenting with acute abdominal pain. Sixty patients were randomized to receive either morphine or placebo; patients and investigators were blinded to which medication the patients received. The study found improvement in pain scores with no changes in abdominal tenderness on examination or clinical diagnostic accuracy.¹⁵² However, this study was limited in size, power calculations were performed post hoc, and the same physicians examined the patients both before and after the study medicine was given. A study by Green et al evaluated children presenting with abdominal pain requiring a surgical consul-

tation. It compared patients receiving placebo to those receiving morphine in a randomized blinded study. Again, pain was improved in the morphine group, with no change in either the pediatric emergency physicians' or the surgeons' confidence in the diagnosis, and there was no difference in patient outcome. Nonetheless, as the authors point out, the study was limited in its ability to account for the potential of missed appendicitis; such a study would require over 1000 participants in order to detect any potential difference.¹⁵³ Similar results were found in a study comparing oxycodone to placebo¹⁵⁴ as well as a study examining time to surgical decision-making, although the latter showed no difference in pain scores between patients receiving morphine and placebo.¹⁵⁵

Despite the absence of evidence that analgesia masks examination findings or alters outcomes in pediatric patients with abdominal pain, there is still skepticism that patients can safely receive pain medicine prior to surgical decision-making. In an editorial by Vane that accompanied the study by Green et al, the author questions the absence of a study decision-making algorithm, and states, "This article has not definitively demonstrated the best algorithm or timing for [analgesia] administration in children with acute abdominal events."¹⁵⁶ Nevertheless, accumulating evidence continues to support the use of analgesia in patients with acute abdominal pain. A meta-analysis of adult and pediatric studies showed that, although there was a change in physical examination findings with analgesia, there was no increase in clinical errors with its use.¹⁵⁷ Similar results were also found in a Cochrane review of adult patients.¹⁵⁸ Use of pain medications for acute abdominal pain in children is reportedly increasing.¹⁵⁹ However, pain is still undertreated, and racial disparities in analgesia exist, as black children are less likely than white children to receive analgesia for abdominal pain.¹⁵ Given all of the current evidence, it is not justifiable to withhold analgesics in pediatric patients with acute abdominal pain.

Lumbar Puncture

LP is performed frequently for pediatric patients in the ED. There is a potential for undertreatment of procedural pain with LP, especially in infants who have limited ability to express pain and discomfort. In a survey of pediatric and emergency medicine residents, residents thought LP pain was less in neonates than toddlers, children, and teens.¹⁶⁰ In a separate survey of emergency medicine attending physicians and pediatric emergency medicine fellows, only 19% of respondents felt that pain experienced by infants during an LP would have any long-term developmental effects.¹⁶¹ These attitudes may lead to less use of analgesia in infants. At a tertiary care children's hospital, pharmacologic procedural pain

relief during LP was used in only 6.5% of neonates and 14.3% of infants, compared to 60% of preschoolers and 85.9% of older children.¹⁶² In a survey of Canadian pediatric emergency medicine physicians, 68% reported using topical anesthesia "often or always,"¹⁶³ while in a separate survey of Canadian general and pediatric ED physicians, 13% of respondents said they would provide no anesthesia to a 3-week-old infant before a lumbar puncture.¹⁶⁴

Despite unfounded attitudes and practices of avoiding analgesia in infants, there is ample evidence suggesting its benefit. In a randomized double-blind placebo-controlled neonatal intensive care unit study, LP was associated with increases in heart rate and behavioral pain scores, but these increases in scores were attenuated with use of EMLA[®] cream.¹⁶⁵ In a prospective unblinded study, use of injectable lidocaine was associated with decreased behavioral pain scores without affecting LP success rate.¹⁶⁶ A similar success rate was found in a second study of injectable lidocaine for LPs, although there was a slight but significant increase in the rate of traumatic LPs in the lidocaine group.¹⁶⁷ Use of topical analgesics has also been associated with decreased use of propofol for sedated LPs.⁶⁶ Improved procedural pain scores have been found with jet-injected lidocaine compared to placebo.⁸² One study found that LPs were significantly more likely to be successful if local analgesia, either topical or injected, was used.¹⁶⁸

The best modality for local anesthesia for LPs is unclear. A recent study found no difference in pain scores in infants receiving needle-free lidocaine versus topical lidocaine, although LP success was higher in the former group.¹⁶⁹ In a study of adult patients, administration of needle-free lidocaine was less painful than injection of lidocaine with no difference in pain scores during the subsequent LP.¹⁷⁰

In summary, strong evidence exists that local anesthesia ameliorates pain during LP in infants. Additionally, using local anesthesia does not decrease—but may improve—LP success rate. Given our knowledge of the detrimental effects of pain in infants and young children, local anesthesia should be utilized in all patients undergoing an LP, regardless of patient age. Adjunct treatments, such as a pacifier dipped in sucrose may also provide some benefit.

Fracture Management

Extremity fractures are often very painful injuries. Despite this, pain in pediatric patients with a fracture is not always recognized and addressed. In a retrospective study of 773 patients presenting to a Level I pediatric trauma center with isolated long-bone fracture requiring hospital admission, only 10% received adequate analgesia, while 59% received no pain medication.¹⁷¹

Younger patients with musculoskeletal injuries are less likely to receive analgesia than older children, likely due to their inability to express pain they are experiencing.^{171,172}

There is a wide range of potential treatment options for fracture pain. One of the first decisions to be made is whether to begin with IV, intranasal, or oral medications. In one study, patients aged > 6 years who did not have an IV but were to receive IV morphine for analgesia for a musculoskeletal injury were randomized to receive either IV morphine or oral oxycodone. Despite longer times to morphine administration, pain scores were lower and patient satisfaction was higher in the IV morphine group.¹⁷³

There are also several studies comparing oral analgesics for fracture pain at ED presentation. One study found a small but statistically significant improvement in pain scores in patients given oxycodone versus codeine, although large doses (0.2 mg/kg oxycodone and 2 mg/kg codeine) were used for both agents.¹⁷⁴ Other similar studies have found ibuprofen for musculoskeletal injuries to be equivalent to acetaminophen with codeine,¹⁷⁵ equivalent to oxycodone or ibuprofen/oxycodone combined,¹⁷⁶ and equivalent to morphine,¹⁴⁴ while another study found it to be superior to codeine or acetaminophen.¹³⁷

Studies on analgesic use at discharge have found similar results. In a double-blind study of 336 pediatric patients with arm fractures who were discharged from the ED, ibuprofen performed at least as well as acetaminophen with codeine for pain control, with fewer adverse effects and greater parental satisfaction.¹⁷⁷ A randomized blinded study found no significant difference in analgesic efficacy between oral ibuprofen and oral morphine in patients discharged from a pediatric ED who had fracture-related pain. Patients in the morphine group had a significantly higher number of adverse events.¹⁷⁸ A smaller study found acetaminophen to be equivalent to ibuprofen in 72 pediatric patients with extremity fractures who were discharged from the ED, although the study was not blinded and ibuprofen was dosed every 8 hours.¹⁷⁹ There is evidence that COX-2 (cyclooxygenase-2) inhibition caused by NSAIDs may delay fracture healing in animal models; however, no definitive clinical effects of this phenomenon have been found in humans.¹⁸⁰

In summary, it is important to recognize the need for pain management in patients with a fracture, particularly in younger patients. For severe pain, IV morphine appears to be superior to oral medications. Intranasal fentanyl appears to be equivalent to IV morphine for pain relief, and it may provide more rapid analgesia in patients with difficult or no IV access. Numerous studies have found no difference between NSAIDs and oral opioids in the treatment of fracture-related pain, both in the ED and at discharge.^{137,144,175-178} Given the risks and side-effect profiles of opioids, ibuprofen should be

the initial medication of choice for mild to moderate fracture pain.

Controversies and Cutting Edge

Regional Anesthesia

Epinephrine-Containing Anesthetics

The use of epinephrine-containing anesthetics on distal body parts such as the nose, penis, fingers, and ears has historically been discouraged for fear of compromising blood flow to these areas. However, multiple studies have not shown any major ischemic complications attributed to epinephrine.¹⁸¹⁻¹⁸⁶

Femoral Nerve Blocks for Femoral Fractures

Due to concern for masking the early signs and symptoms of compartment syndrome, controversy exists concerning the use of femoral nerve blocks for femoral fractures in the ED. However, there are no reports of a femoral nerve block masking acute thigh compartment syndrome or leading to a delay in diagnosis following an acute injury,^{187,188} and complication rates are low.¹⁸⁹ Multiple studies show superior analgesia in patients receiving femoral nerve blocks than those receiving systemic analgesics alone.^{189,190} Opioids are used extensively in the management of pediatric pain associated with femur fractures; however, they have many side effects, including respiratory and cognitive depression, which are not desirable in trauma or pediatric patients. Femoral nerve blocks show promise as a means to reduce the utilization of opioid analgesia and the undesirable side effects, but their use is not yet widespread for pediatric patients in the ED.

Intranasal Ketamine

While ketamine is most frequently used as a dissociative anesthetic for pediatric ED patients, at subdissociative doses, it has analgesic effects. The ability to administer ketamine intranasally makes it a potentially attractive agent to be used in the prehospital setting or when IV access is not immediately available. Multiple studies have prospectively compared intranasal ketamine to intranasal fentanyl. Three studies have compared 1.5 mcg/kg fentanyl to 1 mg/kg ketamine in children with extremity injuries. All of the studies found equivalent pain relief in each group, with greater side effects in the ketamine group.¹⁹¹⁻¹⁹³ Another study found similar results comparing 2 mcg/kg fentanyl to 1.5 mg/kg ketamine.¹⁹⁴

While intranasal ketamine shows promise, its side effect profile and the absence of a large multicenter trial of its effectiveness and the risk of serious adverse events preclude its routine use at this time. Further study of the analgesic effects of ketamine is warranted.

Opioid Misuse

The misuse of opioids is an epidemic. In the United States, drug overdose deaths tripled between 1999 and 2014, with 60.9% of drug deaths in 2014 involving opioids.¹⁹⁵ Rates of intensive care unit admissions for opioid overdoses at children's hospitals doubled between 2004 and 2015, with the majority of these patients being aged 12 to 17 years.¹⁹⁶ The rate of hospital admissions for opioid overdoses in pediatric patients increased by 165% between 1997 and 2012.¹⁹⁷ In many cases, the beginnings of opioid abuse involve contact with the medical community. Thirty-one percent of adults misusing opioids reported that the medication was initially prescribed by a physician for medical reasons.¹⁹⁸ Twenty-two percent of adolescents who were prescribed controlled substances report misusing the medication.¹⁹⁹ Additionally, a prospective survey study found that having a legitimate opioid prescription by twelfth grade was associated with a 33% increase in the risk of future opioid misuse after high school.²⁰⁰

Emergency clinicians need to be judicious about their opioid prescribing patterns without compromising patient analgesia, as the risk of future opioid misuse after a short course of opioids prescribed to a pediatric patient in the ED is unknown. For fracture management, nonopioid analgesics provide analgesia comparable to oral opioids and should be preferentially prescribed. Emergency clinicians should be similarly thoughtful about the need for opioids in other conditions and should also be judicious in the number of doses of medication they prescribe. In one study of 343 discharged pediatric inpatients, 58% of prescribed opioid doses were not consumed.²⁰¹ Quality improvement efforts may help limit numbers of dispensed doses. A study of pediatric EDs and urgent care centers found numbers of dispensed doses of opioids were associated with prescriber training level and care site, independent of patient characteristics.¹³⁹ Limiting patient exposure to opioid medications without compromising care can help limit unintended harm to patients and those around them.

Risk Management Pitfalls for Pediatric Pain Management

(Continued on page 15)

1. **"The patient was wide awake after I pushed his IV morphine, so I thought it was OK to leave him off the monitor."**

Cardiopulmonary monitoring is required for all patients who have been given IV opioids. The time to peak onset of IV morphine is at least 20 minutes. Failure to properly monitor a patient on IV opioids could lead to hypoventilation, apnea, and death.

2. **"The kid was faking it. I had a patient with the same problem last week, and she didn't complain nearly as much!"**

Pain is a multifactorial process. It is influenced not only by the stimulus that is causing the pain but also by the patient's age, temperament, past experiences, and understanding. All of these factors may lead to real, physiologic amplification of a given painful stimulus. It is important to recognize these differences and not minimize patients' self-report of pain.

3. **"Even though I saw the obvious extremity fracture, I thought I should get x-rays to see the extent of the fracture before I gave her pain medication or placed a nerve block."**

Children with pain associated with suspected injuries and/or fractures should be given pain medication prior to imaging. Placing a peripheral nerve block can improve pain associated with obtaining radiographs and splinting.

4. **"I always prescribe opioids to patients with musculoskeletal injuries at the time of discharge to make sure their pain is well controlled."**

Numerous studies have found no difference between NSAIDs and oral opioids in the treatment of fracture-related pain after ED discharge, with opioids having more side effects. Additionally, in one study, receipt of a legitimate opioid prescription as an adolescent was associated with a 33% increase in the risk of opioid misuse later in life.²⁰⁰ While opioids do have a role in the outpatient management of musculoskeletal pain, they should be used judiciously and as part of a care plan that also includes ibuprofen or acetaminophen.

5. **"He's only 4 and would not talk to me. I thought he was just scared; how was I supposed to know he was in pain?"**

The gold standard and most desirable method for pain assessment is based upon self-report of pain by the patient. All children should have pain measured, and pain scales have been validated and developed to assist with pain measurement in preverbal children. The FLACC (see Table 1, page 4) is used to assess preverbal children or children who are unable to communicate pain. The FPS-R and CAS are self-report pain scales that have been used in children as young as 4 years.

Summary

While children with pain may have historically been undertreated or ignored in the name of efficiency, this practice no longer meets acceptable standards of care. We now know that pain causes significant harm to pediatric patients both in the short term and the long term. Techniques have been developed to quantify pain in all age groups and developmental levels. Nonpharmacologic methods have been refined and studied to reduce patients' pain and anxiety in a safe and effective way. The development of newer agents, a greater understanding of older medications, improved experience with and use of procedural sedation, and newer treatment modalities such as ultrasound-guided regional anesthesia have all expanded the armamentarium and approach of emergency clinicians to treating pain in the pediatric population. By being both mindful of the need to treat pain and thoughtful in developing strategies to do so, we may move closer to the goal of the "ouchless" ED for pediatric patients.

Case Conclusions

To quickly address the 8-year-old boy's arm pain, you ordered a dose of intranasal fentanyl at 1.5 mcg/kg. You instructed the nurse to draw up the IV formulation of fentanyl in a syringe and then attached an atomizer to the syringe. The nurse then administered half the dose into each of the patient's nostrils. When you re-evaluated him 5 minutes later, his pain was significantly improved to 3/10. Eventually, the team was able to place an IV, and the boy's fracture was successfully reduced while he was sedated with ketamine. The boy was discharged home, and dosing instructions for ibuprofen as needed for pain were given to his parents. You also provided a prescription for oxycodone for breakthrough pain, with specific instructions on its administration, storage, and disposal.

Since there is no evidence that giving analgesia for pain secondary to an acute abdomen alters either diagnostic confidence or patient outcomes, you discussed with the surgical resident your plan to give the 7-year-old boy with right lower quadrant pain 0.1 mg/kg of IV morphine. You asked the nurse to give him lidocaine at the IV site

Risk Management Pitfalls for Pediatric Pain Management (Continued from page 14)

6. "I didn't need to explain how to dose acetaminophen; it's an over-the-counter drug."

Multiple studies have shown that parents are often inaccurate in their dosing of common analgesics when administering them to their children. This can result in both underdosing and overdosing of these medications. Therefore, it is vital to take the time to make sure parents understand the correct dosing of medications you recommend, even those that are over-the-counter.

7. "I placed my dialysis patient on every-4-hour dosing of morphine, and now he is somnolent and hypoventilating."

One of the molecules morphine is metabolized into is morphine-6-glucuronide, which is an active metabolite. Typically, it is renally excreted, so patients in renal failure may build up toxic levels of this metabolite. In patients with significant renal failure, it is important to renally dose morphine.

8. "No one told me the patient I placed on ketorolac had a history of gastrointestinal bleeding."

Although NSAIDs are frequently used in pediatric patients, they are not without potential side effects. Additionally, as the efficacy of an NSAID increases, so too does its propensity to cause side effects. Take a thorough medical history before deciding which medication to administer to a patient.

9. "The vomiting, dehydrated patient was still febrile, so we repeated the dosing of rectal acetaminophen."

Acetaminophen has a highly variable bioavailability when administered rectally. Additionally, patients in catabolism may be deficient in glutathione, an antioxidant critical in preventing acetaminophen toxicity. Caution should be used to make sure rectal acetaminophen is dosed properly in these patients.

10. "We didn't need to sedate the patient. We just held him down to complete the procedure."

Due both to their size and their developmental limitations, children have limited ability to express pain and advocate for themselves. Although it may be physically possible to perform a painful procedure without analgesia or sedation, this pattern of practice can harm the patient both immediately and into the future. For this reason, it is imperative that emergency clinicians be thoughtful in choosing how to minimize pain during procedures on pediatric patients.

via a needleless syringe prior to IV placement. The IV was placed, and within 5 minutes of morphine administration, his pain improved to 2/10. Later, the surgical team came to evaluate him, and the surgical attending agreed with your decision to treat your patient's pain. The patient was eventually diagnosed with acute appendicitis and underwent a successful removal of a nonperforated appendix.

For the 21-day-old infant who presented with a fever to 38.3°C (100.9°F), you recognized that minimizing procedural pain was beneficial both to the well-being and development of your young patient and has been associated with increased procedural success. You therefore ordered topical lidocaine (LMX[®]) to be placed on the patient's lower back. Thirty minutes later, after the patient's blood and urine studies were obtained, you performed the patient's lumbar puncture. The patient was also provided a small amount of sucrose solution on a pacifier during the procedure. You successfully completed the procedure, and the patient was subsequently admitted to the medical floor on antibiotics pending the results of blood, urine, and cerebrospinal fluid cultures.

Time- and Cost-Effective Strategies

- **Apply topical analgesics early during a patient's visit.** LET requires 20 minutes to achieve the desired effect, LMX[®] requires 30 minutes, and EMLA[®] requires 60 minutes. Early application of these agents can allow for procedures to be completed faster, thereby hastening patient disposition. To this end, a number of centers have established standing orders for the use of topical anesthetics, allowing them to be applied as early as patient triage.
- **Consider using local anesthesia.** Using both local and regional anesthesia can reduce the need for systemic pain medications and potentially eliminate the need for procedural sedation in certain situations. This will decrease both the risk of complications of systemic agents as well as the patient's length of stay.
- **Recognize the value in adequately treating patient pain.** Studies have shown that families are willing to spend both time and money to have their children's procedures be less painful. By appropriately treating patient pain, you will increase patient satisfaction, thereby encouraging future selection of your institution.

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study, such as the type of study and the number of patients in the study is included in bold type following the references, where available. The most informative references cited in this paper, as determined by the authors, are noted by an asterisk (*) next to the number of the reference.

1. Williams AC, Craig KD. Updating the definition of pain. *Pain*. 2016;157(11):2420-2423. **(Review)**
2. Zempsky W. Developing the painless emergency department: a systematic approach to change. *Clin Ped Emerg Med*. 2000;1(4):253-259. **(Review)**
3. Fitzgerald M, Begs S. The neurobiology of pain: developmental aspects. *Neuroscientist*. 2001;7(3):246-257. **(Review)**
4. Grunau RV, Whitfield MF, Petrie JH, et al. Early pain experience, child and family factors, as precursors of somatization: a prospective study of extremely premature and fullterm children. *Pain*. 1994;56(3):353-359. **(Prospective cohort; 72 subjects)**
5. Saigal S, Feeny D, Rosenbaum P, et al. Self-perceived health status and health-related quality of life of extremely low-birth-weight infants at adolescence. *J Am Med Assoc*. 1996;276(6):453-459. **(Prospective cohort; 286 subjects)**
6. Grunau RV, Whitfield MF, Petrie J. Children's judgements about pain at age 8–10 years: do extremely low birthweight (<1000 g) children differ from full term birthweight peers? *J Child Psychol Psychiatry*. 1998;39(4):587-594. **(Prospective cohort; 84 subjects)**
7. Fitzgerald M, Howard R. The neurobiological basis of pediatric pain. In: Schechter N, Berde C, Yaster M, eds. *Pain in Infants, Children, and Adolescents*. 2nd ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2003:19-42. **(Book chapter)**
8. Schechter N, Allen D, Hanson K. Status of pediatric pain control: a comparison of hospital analgesic use in children and adults. *Pediatrics*. 1986;77(1):11-15. **(Retrospective cohort; 180 subjects)**
9. Selbst S, Clark M. Analgesic use in the emergency department. *Ann Emerg Med*. 1990;19(9):1010-1013. **(Retrospective cohort; 268 subjects)**
10. Friedland LR, Pancioli AM, Duncan KM. Pediatric emergency department analgesic practice. *Pediatr Emerg Care*. 1997;13(2):103-106. **(Retrospective review; 1994 subjects)**
11. Neighbor ML, Honner S, Kohn MA. Factors affecting emergency department opioid administration to severely injured patients. *Acad Emerg Med*. 2004;11(12):1290-1296. **(Retrospective cohort; 540 subjects)**
12. Swafford L, Allen D. Pain relief in the pediatric patient. *Med Clin North Am*. 1968;52:133. **(Review)**
13. Lippmann M, Nelson R, Emmanouilides G, et al. Ligation of patent ductus arteriosus in premature infants. *Br J Anaesth*. 1976;48(4):365-369. **(Case series; 24 subjects)**
14. Beyer J, DeGood D, Ashley L, et al. Patterns of postoperative analgesic use with adults and children following cardiac surgery. *Pain*. 1983;17(1):71-81. **(Retrospective cohort; 100 subjects)**

subjects)

15. Goyal MK, Kuppermann N, Cleary SD, et al. Racial disparities in pain management of children with appendicitis in emergency departments. *JAMA Pediatr.* 2015;169(11):996-1002. **(Cross-sectional database study; estimated 940,000 subjects)**
16. Uspal NG, Klein EJ, Tieder JS, et al. Variation in the use of procedural sedation for incision and drainage of skin and soft tissue infection in pediatric emergency departments. *Hosp Pediatr.* 2015;5(4):185-192. **(Retrospective cohort; 6322 cases)**
17. Miller AF, Monuteaux MC, Bourgeois FT, et al. Variation in pediatric procedural sedations across children's hospital emergency departments. *Hosp Pediatr.* 2018;8(1):36-43. **(Retrospective cohort; 99,951 cases)**
18. Schechter N. The undertreatment of pain in children: an overview. *Pediatr Clin North Am.* 1989;36(4):781-794. **(Review)**
19. Melzack R. The challenge of pain in the twenty-first century. In: Melzack R, Walls P, eds. *The Challenge of Pain*. Updated 2nd ed. New York: Penguin Books; 2008. **(Book chapter)**
20. Dinakar P, Stillman AM. Pathogenesis of pain. *Semin Pediatr Neurol.* 2016;23(3):201-208. **(Review)**
21. Walker SM, Beggs S, Baccei ML. Persistent changes in peripheral and spinal nociceptive processing after early tissue injury. *Exp Neurol.* 2016;275(Pt 2):253-260. **(Review)**
- 22.* Taddio A, Katz J, Ilersich A, et al. Effect of neonatal circumcision on pain response during subsequent routine vaccination. *Lancet.* 1997;349(9052):599-603. **(Prospective cohort; 87 subjects)**
23. Weisman SJ, Bernstein B, Schechter NL. Consequences of inadequate analgesia during painful procedures in children. *Arch Pediatr Adolesc Med.* 1998;152(2):147-149. **(Prospective cohort; 21 subjects)**
24. Rennick J, Johnston C, Dougherty G, et al. Children's psychological responses after critical illness and exposure to invasive technology. *J Dev Behav Pediatr.* 2002;23(3):133-144. **(Prospective cohort; 120 subjects)**
25. Pate J, Blount R, Cohen L, et al. Childhood medical experience and temperament as predictors of adult functioning in medical situations. *Children's Health Care.* 1996;25(4):281-298. **(Survey; 147 respondents)**
26. Alonso-Serra H, Wesley K, National Association of EMS Physicians Standards and Clinical Practices Committee. Prehospital pain management. *Prehosp Emerg Care.* 2003;7(4):482-488. **(Consensus guideline)**
27. Fein JA, Zempsky WT, Cravero JP, et al. Relief of pain and anxiety in pediatric patients in emergency medical systems. *Pediatrics.* 2012;130(5):e1391-e1405. **(Consensus guideline)**
28. Gausche-Hill M, Brown KM, Oliver ZJ, et al. An evidence-based guideline for prehospital analgesia in trauma. *Prehosp Emerg Care.* 2014;18(Suppl 1):25-34. **(Consensus guideline)**
- 29.* Brown KM, Hirshon JM, Alcorta R, et al. The implementation and evaluation of an evidence-based statewide prehospital pain management protocol developed using the national prehospital evidence-based guideline model process for emergency medical services. *Prehosp Emerg Care.* 2014;18(Suppl 1):45-51. **(Retrospective comparative study; 2128 subjects)**
30. Alexander J, Manno M. Underuse of analgesia in very young pediatric patients with isolated painful injury. *Ann Emerg Med.* 2003;41(5):617-622. **(Retrospective cohort; 180 subjects)**
31. Browne LR, Shah MI, Studnek JR, et al. Multicenter evaluation of prehospital opioid pain management in injured children. *Prehosp Emerg Care.* 2016;20(6):759-767. **(Retrospective comparison study; 7340 subjects)**
32. Browne LR, Studnek JR, Shah MI, et al. Prehospital opioid administration in the emergency care of injured children. *Prehosp Emerg Care.* 2016;20(1):59-65. **(Retrospective cross-sectional study; 1368 subjects)**
33. Murphy A, McCoy S, O'Reilly K, et al. A prevalence and management study of acute pain in children attending emergency departments by ambulance. *Prehosp Emerg Care.* 2016;20(1):52-58. **(Retrospective cross-sectional study; 6371 subjects)**
34. Galinski M, Picco N, Hennequin B, et al. Out-of-hospital emergency medicine in pediatric patients: prevalence and management of pain. *Am J Emerg Med.* 2011;29(9):1062-1066. **(Prospective cohort; 258 subjects)**
35. Johnston C, Gagnon A, Fullerton L, et al. One-week survey of pain intensity on admission to and discharge from the emergency department: a pilot study. *J Emerg Med.* 1998;16(3):377-382. **(Prospective cross-sectional pilot study; 286 subjects)**
36. Rogovik AL, Goldman RD. Prehospital use of analgesics at home or en route to the hospital in children with extremity injuries. *Am J Emerg Med.* 2007;25(4):400-405. **(Prospective cohort study; 310 subjects)**
37. Hennes H, Kim MK, Pirrallo RG. Prehospital pain management: a comparison of providers' perceptions and practices. *Prehosp Emerg Care.* 2005;9(1):32-39. **(Survey; 155 respondents)**
38. Rahman A, Curtis S, DeBruyne B, et al. Emergency medical services provider comfort with prehospital analgesia administration to children. *Prehosp Disaster Med.* 2015;30(1):66-71. **(Survey; 191 subjects)**
39. Izsak E, Moore JL, Stringfellow K, et al. Prehospital pain assessment in pediatric trauma. *Prehosp Emerg Care.* 2008;12(2):182-186. **(Retrospective chart review, 696 subjects)**
40. Ward ME, Radburn J, Morant S. Evaluation of intravenous tramadol for use in the prehospital situation by ambulance patients. *Prehospital Disaster Med.* 1997;12(2):158-162. **(Prospective case-control; 142 subjects)**
41. Vergnion M, Degesves S, Garcet L, et al. Tramadol, an alternative to morphine for treating posttraumatic pain in the prehospital situation. *Anesth Analg.* 2001;92(6):1543-1546. **(Randomized double-blind parallel study; 105 subjects)**
42. Bruns BM, Dieckmann R, Shagoury C, et al. Safety of prehospital therapy with morphine sulfate. *Am J Emerg Med.* 1992;10(1):53-57. **(Prospective cross-sectional study; 84 subjects)**
43. DeVellis P, Thomas SH, Wedel SK, et al. Prehospital fentanyl analgesia in air-transported pediatric trauma patients. *Pediatr Emerg Care.* 1998;14(5):321-323. **(Retrospective cohort; 131 subjects)**
44. Karlsen AP, Pedersen DM, Trauter S, et al. Safety of intranasal fentanyl in the out-of-hospital setting: a prospective observational study. *Ann Emerg Med.* 2014;63(6):699-703. **(Prospective observational study; 903 subjects)**
45. Bendall J, Simpson P, Middleton P. Effectiveness of prehospital morphine, fentanyl, and methoxyflurane in pediatric patients. *Prehosp Emerg Care.* 2011;15(2):158-165. **(Retrospective comparative study; 3312 subjects)**
46. Reid C, Hatton R, Middleton P. Case report: prehospital use of intranasal ketamine for paediatric burn injury. *Emerg Med J.* 2011;28(4):328-329. **(Case report)**
47. Schauer SG, Arana AA, Naylor JF, et al. Prehospital analgesia for pediatric trauma patients in Iraq and Afghanistan. *Prehosp Emerg Care.* 2018;22(5):608-613. **(Retrospective cohort study; 3439 subjects)**
48. Buckland DM, Crowe RP, Cash RE, et al. Ketamine in the prehospital environment: a national survey of paramedics

- in the United States. *Prehosp Disaster Med.* 2018;33(1):23-28. **(Survey; 14,739 respondents)**
49. Joint Commission on Accreditation of Healthcare Organizations. *2018 Comprehensive Accreditation Manual for Hospitals.* Oakbrook Terrace, IL: Joint Commission Resources; 2018. **(Consensus guideline)**
 50. Kochman A, Howell J, Sheridan M, et al. Reliability of the Faces, Legs, Activity, Cry, and Consolability Scale in assessing acute pain in the pediatric emergency department. *Pediatr Emerg Care.* 2017;33(1):14-17. **(Prospective observational study; 66 subjects)**
 51. Stinson JN, Kavanagh T, Yamada J, et al. Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents. *Pain.* 2006;125(1-2):143-157. **(Systematic review)**
 52. Birnie KA, Hundert AS, Laloo C, et al. Recommendations for selection of self-report pain intensity measures in children and adolescents: a systematic review and quality assessment of measurement properties. *Pain.* 2019;160(1):5-18. **(Systematic review)**
 53. Bailey B, Bergeron S, Gravel J, et al. Comparison of four pain scales in children with acute abdominal pain in a pediatric emergency department. *Ann Emerg Med.* 2007;50(4):379-383. **(Randomized controlled trial; 84 subjects)**
 54. Tsze DS, Hirschfeld G, Dayan PS, et al. Defining no pain, mild, moderate, and severe pain based on the faces pain scale-revised and color analog scale in children with acute pain. *Pediatr Emerg Care.* 2018;34(8):537-544. **(Prospective observational study; 620 subjects)**
 55. Brandow AM, Weisman SJ, Panepinto JA. The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations. *Pediatr Blood Cancer.* 2011;56(5):789-793. **(Retrospective cohort study; 19 subjects)**
 56. Richardson J, Smith JE, McCall G, et al. Hypnosis for procedure-related pain and distress in pediatric cancer patients: a systematic review of effectiveness and methodology related to hypnosis interventions. *J Pain Symptom Manage.* 2006;31(1):70-84. **(Systematic review)**
 57. Evans S, Tsao JC, Zeltzer LK. Complementary and alternative medicine for acute procedural pain in children. *Altern Ther Health Med.* 2008;14(5):52-56. **(Review)**
 58. Boughton K, Blower C, Chartand C, et al. Impact of research on pediatric pain assessment and outcomes. *Pediatr Nurs.* 1998;24(1):31-35. **(Prospective interventional study; 36 subjects)**
 59. Ellis JA, Sharp D, Newhook K, et al. Selling comfort: a survey of interventions for needle procedures in a pediatric hospital. *Pain Manag Nurs.* 2004;5(4):144-152. **(Survey of practice and review)**
 60. Vincent C, Denyes M. Relieving children's pain: nurses' abilities and analgesic administration practices. *J Pediatr Nurs.* 2004;19(1):40-50. **(Observational study of convenience sample; 67 subjects)**
 - 61.* Birnie KA, Noel M, Chambers CT, et al. Psychological interventions for needle-related procedural pain and distress in children and adolescents. *Cochrane Database Syst Rev.* 2018;10:CD005179. **(Systematic review; 59 studies)**
 62. Martin V. Using distraction techniques with children. *Nursing.* 2013;43(11):68. **(Review)**
 63. Pillai Riddell R, Racine NM, Gennis HG, et al. Non-pharmacological management of infants and young child procedural pain. *Cochrane Database Syst Rev.* 2015;12:CD006275-006271. **(Meta-analysis; 63 studies)**
 64. Harrison D, Reszel J, Bueno M, et al. Breastfeeding for procedural pain in infants beyond the neonatal period. *Cochrane Database Syst Rev.* 2016;10:CD011248. **(Systematic review; 10 studies)**
 65. Taddio A, Soin HK, Schuh S, et al. Liposomal lidocaine to improve procedural success rate and reduce procedural pain among children: a randomized controlled trial. *CMAJ.* 2005;172(13):1691-1695. **(Randomized placebo-controlled study; 142 subjects)**
 66. Whitlow PG, Saboda K, Roe DJ, et al. Topical analgesia treats pain and decreases propofol use during lumbar punctures in a randomized pediatric leukemia trial. *Pediatr Blood Cancer.* 2015;62(1):85-90. **(Randomized cross-over trial; 26 subjects)**
 67. Algren CL, Algren JT. Pain management in children. *Plast Surg Nurs.* 1994;14(2):65-70. **(Review)**
 68. Young K. What's new in topical anesthesia. *Clin Ped Emerg Med.* 2007;8(4):232-239. **(Review)**
 69. Zempsky W, Robbins B, McKay K. Reduction of topical anesthetic onset time using ultrasound: a randomized controlled trial prior to venipuncture in young children. *Pain Med.* 2008;9(7):795-802. **(Randomized controlled trial; 70 subjects)**
 70. Fetzer S. Reducing venipuncture and intravenous insertion pain with eutectic mixture of local anesthetic: a meta-analysis. *Nurs Res.* 2002;51(2):119-124. **(Meta-analysis; 20 studies)**
 71. Shachor-Meyouhas Y, Galbraith R, Shavit I. Application of topical analgesia in triage: a potential for harm. *J Emerg Med.* 2008;35(1):39-41. **(Case report and review)**
 72. Liebelt EL. Reducing pain during procedures. *Curr Opin Pediatr.* 1996;8(5):436-441. **(Review)**
 73. Schreiber S, Ronfani L, Chiaffoni GP, et al. Does EMLA cream application interfere with the success of venipuncture or venous cannulation? A prospective multicenter observational study. *Eur J Pediatr.* 2013;172(2):265-268. **(Prospective observational study; 388 subjects)**
 74. Eichenfield LF, Funk A, Fallon-Friedlander S, et al. A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. *Pediatrics.* 2002;109(6):1093-1099. **(Randomized controlled crossover trial; 120 subjects)**
 75. Koh J, Harrison D, Myers R, et al. A randomized, double-blind comparison study of EMLA and ELA-max for topical anesthesia in children undergoing intravenous insertion. *Paediatr Anaesth.* 2004;14(12):977-982. **(Randomized controlled trial; 60 subjects)**
 76. Poonai N, Alawi K, Rieder M, et al. A comparison of amethocaine and liposomal lidocaine cream as a pain reliever before venipuncture in children: a randomized control trial. *Pediatr Emerg Care.* 2012;28(2):104-108. **(Randomized controlled trial; 60 subjects)**
 - 77.* Lunoe MM, Drendel AL, Levas MN, et al. A randomized clinical trial of jet-injected lidocaine to reduce venipuncture pain for young children. *Ann Emerg Med.* 2015;66(5):466-474. **(Randomized controlled trial; 205 subjects)**
 78. Spanos S, Booth R, Koenig H, et al. Jet injection of 1% buffered lidocaine versus topical ELA-max for anesthesia before peripheral intravenous catheterization in children: a randomized controlled trial. *Pediatr Emerg Care.* 2008;24(8):511-515. **(Randomized controlled trial; 70 subjects)**
 79. Jimenez N, Bradford H, Seidel KD, et al. A comparison of a needle-free injection system for local anesthesia versus EMLA for intravenous catheter insertion in the pediatric patient. *Anesth Analg.* 2006;102(2):411-414. **(Nonblinded randomized study; 116 subjects)**
 80. Lunoe MM, Drendel AL, Brousseau DC. The use of the needle-free jet injection system with buffered lidocaine device does not change intravenous placement success in children in the emergency department. *Acad Emerg Med.* 2015;22(4):447-451. **(Retrospective cohort study; 958 subjects)**

81. Auerbach M, Tunik M, Mojica M. A randomized, double-blind controlled study of jet lidocaine compared to jet placebo for pain relief in children undergoing needle insertion in the emergency department. *Acad Emerg Med.* 2009;16(5):388-393. **(Randomized controlled trial; 150 subjects)**
82. Ferayomi A, Yniquez R, Bryson M, et al. Needle-free jet injection of lidocaine for local anesthesia during lumbar puncture: a randomized controlled trial. *Pediatr Emerg Care.* 2012;28(7):687-690. **(Randomized controlled trial; 55 subjects)**
83. Eidelman A, Weiss JM, Enu IK, et al. Comparative efficacy and costs of various topical anesthetics for repair of dermal lacerations: a systematic review of randomized, controlled trials. *J Clin Anesth.* 2005;17(2):106-116. **(Systematic review of randomized controlled trials)**
84. Ferguson C, Loryman B, Body R. Best evidence topic report: topical anaesthetic versus lidocaine infiltration to allow closure of skin wounds in children. *Emerg Med J.* 2005;22(7):507-509. **(Systematic review)**
85. Singer AJ, Stark MJ. Pretreatment of lacerations with lidocaine, epinephrine, and tetracaine at triage: a randomized double-blind trial. *Acad Emerg Med.* 2000;7(7):751-756. **(Randomized controlled trial; 43 subjects)**
86. Priestley S, Kelly AM, Chow L, et al. Application of topical local anesthetic at triage reduces treatment time for children with lacerations: a randomized controlled trial. *Ann Emerg Med.* 2003;42(1):34-40. **(Randomized controlled trial; 161 subjects)**
87. Griffith RJ, Jordan V, Herd D, et al. Vapocoolants (cold spray) for pain treatment during intravenous cannulation. *Cochrane Database Syst Rev.* 2016;4:CD009484. **(Systematic review; 9 studies)**
88. Gottlieb M, Hunter B. Effect of vapocoolant on pain during peripheral intravenous cannulation. *Ann Emerg Med.* 2016;68(5):586-588. **(Commentary)**
89. Dalvandi A, Ranibar H, Hatamizadeh M, et al. Comparing the effectiveness of vapocoolant spray and lidocaine/procaine cream in reducing pain of intravenous cannulation: a randomized clinical trial. *Am J Emerg Med.* 2017;35(8):1064-1068. **(Randomized clinical trial; 40 subjects)**
90. Selbst SM. Managing pain in the pediatric emergency department. *Pediatr Emerg Care.* 1989;5(1):56-63. **(Review)**
91. Lönnqvist P. Toxicity of local anesthetic drugs: a pediatric perspective. *Paediatr Anaesth.* 2012;22(1):39-43. **(Review)**
92. Di Gregorio G, Neal JM, Rosenquist RW, et al. Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. *Reg Anesth Pain Med.* 2010;35(2):181-187. **(Systematic review; 93 cases)**
93. Christoph R, Buchanan L, Begalla K, et al. Pain reduction in local anesthetic administration through pH buffering. *Ann Emerg Med.* 1988;17(2):117-120. **(Randomized controlled trial; 25 subjects)**
94. Cepeda M, Tzortzopoulou A, Thackrey M, et al. Adjusting the pH of lidocaine for reducing pain on injection. *Cochrane Database Syst Rev.* 2010;Dec 8(12):CD006581. **(Meta-analysis; 23 studies)**
95. Parris P. Transcutaneous nerve stimulation. *Emerg Med J.* 1986;18:57-60. **(Review)**
96. Hogan M, Perampaladas K, Machado M, et al. Systematic review and meta-analysis of the effect of warming local anesthetics on injection pain. *Ann Emerg Med.* 2011;58(1):86-98. **(Meta-analysis; 19 studies)**
97. Crystal C, Blankenship RB. Local anesthetics and peripheral nerve blocks in the emergency department. *Emerg Med Clin North Am.* 2005;23(2):477-502. **(Review)**
98. Bhoi S, Sinha TP, Rodha M, et al. Feasibility and safety of ultrasound-guided nerve block for management of limb injuries by emergency care physicians. *J Emerg Trauma Shock.* 2012;5(1):28-32. **(Prospective observational study; 50 subjects)**
99. Penna A, Buchanan N. Paracetamol poisoning in children and hepatotoxicity. *Br J Clin Pharmacol.* 1991;32(2):143-149. **(Review)**
100. Muniz A, Rose S, Liner S, et al. Unsuspected acetaminophen toxicity in a 58 day old infant. *Ped Emerg Care.* 2004;20(12):824-828. **(Case report)**
101. Goldman RD, Scolnik D. Underdosing of acetaminophen by parents and emergency department utilization. *Pediatr Emerg Care.* 2004;20(2):89-93. **(Cross-sectional observational study; 248 subjects)**
102. Li S, Lacher B, Crain E. Acetaminophen and ibuprofen dosing by parents. *Pediatr Emerg Care.* 2000;16(6):394-397. **(Cross-sectional observational study; 200 subjects)**
103. Kraemer F, Rose J. Pharmacologic management of acute pediatric pain. *Anesthesiol Clin.* 2009;27(2):241-268. **(Review)**
104. Birmingham P, Tobin M, Henthorn T, et al. Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations. *Anesthesiology.* 1997;87(2):244-252. **(Randomized clinical trial; 28 subjects)**
105. Osterhoudt K, Henretig F. Still wary of rectal acetaminophen. *Arch Pediatr Adolesc Med.* 2009;163(5):491. **(Letter)**
106. Babl FE, Theophilos T, Palmer GM. Is there a role for intravenous acetaminophen in pediatric emergency departments? *Pediatr Emerg Care.* 2011;27(6):496-499. **(Retrospective observational study; 31 subjects)**
107. Mak W, Yuen V, Irwin M, et al. Pharmacotherapy for acute pain in children: current practice and recent advances. *Expert Opin Pharmacother.* 2011;12(6):865-881. **(Systematic review)**
108. Holubek W, Stolbach A, Nurok S, et al. A report of two deaths from massive ibuprofen ingestion. *J Med Toxicol.* 2007;3(2):52-55. **(Case series; 2 cases)**
109. Levine M, Khurana A, Ruha AM. Polyuria, acidosis, and coma following massive ibuprofen ingestion. *J Med Toxicol.* 2010;6(3):315-317. **(Case report)**
110. Perrott D, Piira T, Goodenough B, et al. Efficacy and safety of acetaminophen versus ibuprofen for treating children's pain or fever. *Arch Pediatr Adolesc Med.* 2004;158(6):521-526. **(Meta-analysis; 17 studies)**
111. Goldman R, Ko K, Linett L, et al. Antipyretic efficacy and safety of ibuprofen and acetaminophen in children. *Ann Pharmacother.* 2004;38(1):146-150. **(Meta-analysis; 14 studies)**
112. Pierce C, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. *Ann Pharmacother.* 2010;44(3):489-506. **(Meta-analysis; 85 studies)**
113. Hartling L, Ali S, Dryden DM, et al. How safe are common analgesics for the treatment of acute pain for children? A systematic review. *Pain Res Manag.* 2016;2016:5346819. **(Meta-analysis; 44 studies)**
114. Le May S, Ali S, Khadra C, et al. Pain management of pediatric musculoskeletal injury in the emergency department: a systematic review. *Pain Res Manag.* 2016;2016:4809394. **(Meta-analysis; 44 studies)**
115. Sjoukes A, Vemekamp RP, van de Pol AC, et al. Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. *Cochrane Database Syst Rev.* 2016;12:CD011534. **(Meta-analysis; 3 studies)**
116. Sheehan WJ, Mauger DT, Paul IM, et al. Acetaminophen versus ibuprofen in young children with mild persistent asthma. *N Engl J Med.* 2016;375(21):619-630. **(Randomized parallel group trial; 300 subjects)**

117. Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. *N Engl J Med*. 1985;313(14):849-857. **(Retrospective case-control; 175 subjects)**
118. Lexicomp Online[®], Lexi-Drugs[®], Hudson, Ohio: Lexi-Comp, Inc. Wolter Kluwer. <https://www.wolterskluwer.com/lexicomp-online/>. Accessed July 15, 2019. **(Drug information database)**
119. Buck ML, Norwood VF. Ketorolac-induced acute renal failure in a previously healthy adolescent. *Pediatrics*. 1996;98(2 Pt 1):294-296. **(Case report)**
120. Houck CS, Wilder RT, McDermott JS, et al. Safety of intravenous ketorolac therapy in children and cost savings with a unit dosing system. *J Pediatr*. 1996;129(2):292-296. **(Prospective study; 1747 subjects)**
121. Marzuillo P, Calligaris L, Amoroso S, et al. Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children. *Acta Paediatr*. 2018;107(4):560-567. **(Systematic review)**
122. Product information: INDOCIN[®] oral capsules, oral suspension, suppositories, indomethacin oral capsules, oral suspension, suppositories. Whitehouse Station, NY: Merck & Co, Inc; 2007. **(Product information)**
123. Krause I, Cleper R, Eisenstein B, et al. Acute renal failure, associated with non-steroidal anti-inflammatory drugs in healthy children. *Pediatr Nephrol*. 2005;20(9):1295-1298. **(Case series; 7 subjects)**
124. Lesko S, Louik C, Vezina R, et al. Asthma morbidity after the short-term use of ibuprofen in children. *Pediatrics*. 2002;109(2):e20. **(Randomized clinical trial; 1879 subjects)**
125. Lewis SR, Nicholson A, Cardwell ME, et al. Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy. *Cochrane Database Syst Rev*. 2013;7:CD003591. **(Meta-analysis; 15 studies)**
126. Riggan L, Ramakrishna J, Sommer DD, et al. A 2013 updated systematic review & meta-analysis of 36 randomized controlled trials; no apparent effects of non steroidal anti-inflammatory agents on the risk of bleeding after tonsillectomy. *Clin Otolaryngol*. 2013;38(2):115-129. **(Meta-analysis; 36 studies)**
127. Lesko S, Mitchell A. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. *JAMA Pediatr*. 1995;273(12):929-933. **(Randomized controlled trial; 84,192 subjects)**
128. United States Food & Drug Administration. FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-restricts-use-prescription-codeine-pain-and-cough-medicines>. Accessed July 15, 2019. **(Regulatory communication)**
129. Government of Canada. Summary Safety Review - Codeine-containing products - further assessing the risk of serious breathing problems in children and adolescents. Available at: <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-codeine-prescription-products-cough-further-assessing-risk-serious.html>. Accessed July 15, 2019. **(Regulatory communication)**
130. European Medicines Agency. PRAC recommends restricting the use of codeine when used for pain relief in children. Available at: https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-recommends-restricting-use-codeine-when-used-pain-relief-children_en.pdf. Accessed July 15, 2019. **(Regulatory communication)**
131. Kraemer F. Treatment of acute pediatric pain. *Semin Pediatr Neurol*. 2010;17(4):268-274. **(Review)**
132. Desmeules J, Gascon M, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. *Eur J Clin Pharmacol*. 1991;41(1):23-26. **(Randomized controlled trial; 8 subjects)**
133. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med*. 2004;351(27):2827-2831. **(Case report)**
134. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. *Lancet*. 2006;368(9536):704. **(Case report)**
135. Goldman JL, Baugh RF, Davies L, et al. Mortality and major morbidity after tonsillectomy: etiologic factors and strategies for prevention. *Laryngoscope*. 2013;123(10):2544-2553. **(Survey study; 552 respondents)**
136. Le May S, Gouin S, Fortin C, et al. Efficacy of an ibuprofen/codeine combination for pain management in children presenting to the emergency department with a limb injury: a pilot study. *J Emerg Med*. 2013;44(2):536-542. **(Randomized controlled trial; 81 subjects)**
137. Clark E, Plint AC, Correll R, et al. A randomized, controlled trial of acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal trauma. *Pediatrics*. 2007;119(3):460-467. **(Randomized controlled trial; 300 patients)**
138. Rodieux F, Vutskits L, Posfay-Barbe KM, et al. When the safe alternative is not that safe: tramadol prescribing in children. *Front Pharmacol*. 2018;9:148. **(Review)**
139. DePhillips M, Watts J, Lowry J, et al. Opioid prescribing practices in pediatric acute care settings. *Pediatr Emerg Care*. 2019;35(1):16-21. **(Retrospective chart review; 3991 cases)**
140. Kirvela M, Lindgren L, Seppola T. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. *J Clin Anesth*. 1996;8(1):13-18. **(Clinical trial; 10 subjects)**
141. Johnson A. Opiates. *Clin Ped Emerg Med*. 2000;1(5):328-333. **(Review)**
142. Bouwmeester N, Anderson B, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. *Br J Anaesth*. 2004;92(2):208-217. **(Randomized controlled trial; 184 subjects)**
143. Lynn A, Slaterry J. Morphine pharmacokinetics in early infancy. *Anesthesiology*. 1987;66(2):136-139. **(Observational study; 10 subjects)**
144. Le May S, Ali S, Plint AC, et al. Oral analgesics utilization for children with musculoskeletal injury (OUCH Trial): an RCT. *Pediatrics*. 2017;140(5). **(Randomized controlled trial; 456 subjects)**
- 145.* Borland M, Jacobs I, King B, et al. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. *Ann Emerg Med*. 2007;49(3):335-340. **(Randomized controlled trial; 67 subjects)**
146. Wolfe T. Intranasal fentanyl for acute pain: techniques to enhance efficacy. *Ann Emerg Med*. 2007;49(5):721-722. **(Letter)**
147. Borland M, Milsom S, Esson A. Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial. *Emerg Med Australas*. 2011;23(2):202-208. **(Randomized controlled trial; 189 subjects)**
148. Holdgate A, Cao A, Lo K. The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration. *Acad Emerg Med*. 2010;17(2):214-217. **(Retrospective**

comparative study; 181 subjects)

149. Murphy A, O'Sullivan R, Wakai A, et al. Intranasal fentanyl for the management of acute pain in children. *Cochrane Database Syst Rev*. 2014;10:CD009942. **(Systematic review; 3 studies)**
150. Miner JR, Kletti C, Herold M, et al. Randomized clinical trial of nebulized fentanyl citrate versus IV fentanyl citrate in children presenting to the emergency department with acute pain. *Acad Emerg Med*. 2007;14(10):895-898. **(Randomized clinical trial; 41 subjects)**
151. Furyk JS, Grabowski WJ, Black LH. Nebulized fentanyl versus intravenous morphine in children with suspected limb fractures in the emergency department: a randomized controlled trial. *Emerg Med Australas*. 2009;21(3):203-209. **(Randomized clinical trial; 73 subjects)**
152. Kim M, Strait R, Sato T, et al. A randomized clinical trial of analgesia in children with acute abdominal pain. *Acad Emerg Med*. 2002;9(4):281-287. **(Randomized controlled trial; 60 subjects)**
- 153.*Green R, Buloch B, Kabani A, et al. Early analgesia for children with acute abdominal pain. *Pediatrics*. 2005;116(4):978-983. **(Randomized controlled trial; 108 subjects)**
154. Kokki H, Lintula H, Vanamo K, et al. Oxycodone versus placebo in children with undifferentiated abdominal pain: a randomized, double-blind clinical trial of the effect of analgesia on diagnostic accuracy. *Arch Pediatr Adolesc Med*. 2005;159(4):320-325. **(Randomized controlled trial; 63 subjects)**
155. Bailey B, Bergeron S, Gravel J, et al. Efficacy and impact of intravenous morphine before surgical consultation in children with right lower quadrant pain suggestive of ap-pendicitis: a randomized controlled trial. *Ann Emerg Med*. 2007;50(4):371-378. **(Randomized controlled trial; 90 subjects)**
156. Vane DW. Efficacy and concerns regarding early analgesia in children with acute abdominal pain. *Pediatrics*. 2005;116(4):1018-1018. **(Commentary)**
157. Ranji SR, Goldman LE, Simel DL, et al. Do opiates affect the clinical evaluation of patients with acute abdominal pain? *JAMA*. 2006;296(14):1764-1774. **(Meta-analysis; 11 studies)**
158. Manterola C, Vial M, Moraga J, et al. Analgesia in patients with acute abdominal pain. *Cochrane Database Syst Rev*. 2011;July 18(3):CD005660. **(Meta-analysis; 8 studies)**
159. Poonai N, Cowie A, Davidson C, et al. Reported provision of analgesia to patients with acute abdominal pain in Canadian paediatric emergency departments. *CJEM*. 2016;18(5):323-330. **(Survey; 149 respondents)**
160. Breakey V, Pirie J, Goldman R. Pediatric and emergency medicine residents' attitudes and practices for analgesia and sedation during lumbar puncture in pediatric patients. *Pediatrics*. 2007;119(3):e631-e636. **(Survey; 245 respondents)**
161. Hoyle J, Rogers A, Reischman D, et al. Pain intervention for infant lumbar puncture in the emergency department: physician practice and beliefs. *Acad Emerg Med*. 2011;18(2):140-144. **(Survey; 156 respondents)**
162. Fein D, Avner J, Khine H. Pattern of pain management during lumbar puncture in children. *Ped Emerg Care*. 2010;26(5):357-360. **(Retrospective review; 353 subjects)**
163. Ali S, Chambers A, Johnson DW, et al. Reported practice variation in pediatric pain management: a survey of Canadian pediatric emergency physicians. *CJEM*. 2014;16(5):352-360. **(Survey; 139 respondents)**
164. Poonai N, Brzozowski V, Stang AS, et al. Pain management practices surrounding lumbar punctures in children: a survey of Canadian emergency physicians. *CJEM*. 2019;21(2):199-203. **(Survey; 406 respondents)**
165. Kaur G, Gupta P, Kumar A. A randomized trial of eutectic mixture of local anesthetics during lumbar puncture in newborns. *Arch Pediatr Adolesc Med*. 2003;157(11):1065-1070. **(Randomized controlled trial; 200 subjects)**
166. Pinheiro J, Furdon S, Ochoa L. Role of local anesthesia during lumbar puncture in neonates. *Pediatrics*. 1993;91(2):379-382. **(Randomized controlled trial; 100 subjects)**
167. Carraccio C, Feinberg P, Hart L, et al. Lidocaine for lumbar punctures: a help not a hindrance. *Arch Pediatr Adolesc Med*. 1996;150(10):1044-1046. **(Randomized controlled trial; 200 subjects)**
- 168.*Baxter A, Fisher R, Burke B, et al. Local anesthetic and stylet styles: factors associated with resident lumbar puncture success. *Pediatrics*. 2006;117(3):876-881. **(Prospective observational study; 428 subjects)**
169. Caltagirone R, Raghavan VR, Adelgaiz K, et al. A randomized double blind trial of needle-free injected lidocaine versus topical anesthesia for infant lumbar puncture. *Acad Emerg Med*. 2018;25(3):310-316. **(Randomized controlled trial; 66 subjects)**
170. Hajimaghsoudi M, Vahidi E, Momeni M, et al. Comparison of local anesthetic effect of lidocaine by jet injection vs needle infiltration in lumbar puncture. *Am J Emerg Med*. 2016;34(7):1225-1229. **(Randomized controlled trial; 65 subjects)**
171. Dong L, Donaldson A, Metzger R, et al. Analgesic administration in the emergency department for children requiring hospitalization for long-bone fracture. *Pediatr Emerg Care*. 2012;28(2):109-114. **(Retrospective cohort study; 773 subjects)**
172. Kircher J, Drendel AL, Newton AS, et al. Acute pediatric musculoskeletal pain management in North America: a practice variation survey. *Clin Pediatr (Phila)*. 2014;53(14):1326-1335. **(Survey; 683 respondents)**
173. Miner J, Moore J, Gray Ret a. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department. *Acad Emerg Med*. 2008;15(12):1234-1240. **(Randomized controlled trial; 328 subjects)**
174. Charney R, Yan Y, Schotman M, et al. Oxycodone versus codeine for triage pain in children with suspected forearm fracture: a randomized controlled trial. *Pediatr Emerg Care*. 2008;24(9):595-600. **(Randomized controlled trial; 107 subjects)**
175. Friday J, Kanegaye J, McCaslin I, et al. Ibuprofen provides analgesia equivalent to acetaminophen-codeine in the treatment of acute pain in children with extremity injuries: a randomized clinical trial. *Acad Emerg Med*. 2009;16(8):711-716. **(Randomized controlled trial; 66 subjects)**
176. Koller DM, Myers AB, Lorenz D, et al. Effectiveness of oxycodone, ibuprofen, or the combination in the initial management of orthopedic injury-related pain in children. *Pediatr Emerg Care*. 2007;23(9):627-633. **(Randomized controlled trial; 66 subjects)**
- 177.*Drendel A, Gorelick M, Weisman S, et al. A randomized clinical trial of ibuprofen versus acetaminophen with codeine for acute pediatric arm fracture pain. *Ann Emerg Med*. 2009;54(4):553-560. **(Randomized controlled trial; 336 subjects)**
178. Poonai N, Bhullar G, Lin K, et al. Oral administration of morphine versus ibuprofen to manage postfracture pain in children: a randomized trial. *CMAJ*. 2014;186(18):1358-1363. **(Randomized clinical trial; 134 subjects)**
179. Shepard M, Aicken R. Paracetamol versus ibuprofen: a randomized controlled trial of outpatient analgesia efficacy for paediatric acute limb fractures. *Emerg Med Australas*. 2009;21(6):484-490. **(Randomized controlled trial; 72 subjects)**

180. Kurmis AP, Kurmis TP, O'Brien JX, et al. The effect of nonsteroidal anti-inflammatory drug administration on acute phase fracture healing: a review. *J Bone Joint Surg Am*. 2012;94(9):815-823. **(Meta-analysis; 318 studies)**
181. Denkler K. A comprehensive review of epinephrine in the finger: to do or not to do. *Plast Reconstr Surg*. 2001;108(1):114-124. **(Review)**
182. Krunic AL, Wang LC, Soltani K. Digital anesthesia with epinephrine: an old myth revisited. *J Am Acad Dermatol*. 2004;51(5):755-759. **(Review)**
183. Muck AE, Bebart VS, Borys DJ, et al. Six years of epinephrine digital injections: absence of significant local or systemic effects. *Ann Emerg Med*. 2010;56(3):270-274. **(Retrospective cohort study; 365 subjects)**
184. Chowdhry S, Seidenstricker L, Cooney DS. Do not use epinephrine in digital blocks: myth or truth? Part II. A retrospective review of 1111 cases. *Plast Reconstr Surg*. 2010;126(6):2031-2034. **(Retrospective review; 1111 subjects)**
185. Mohan PP. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary: epinephrine in digital nerve block. *Emerg Med J*. 2007;24(11):789-790. **(Review)**
186. Lalonde D, Bell M, Benoit P. A multicenter prospective study of 3,110 consecutive cases of elective epinephrine use in the fingers and hand: the Dalhousie Project clinical phase. *J Hand Surg Am*. 2005;30(5):1061-1067. **(Prospective observational study; 3110 subjects)**
187. Karaginnis G, Hardern R. No evidence found that a femoral nerve block in cases of femoral shaft fractures can delay the diagnosis of compartment syndrome of the thigh. *Emerg Med J*. 2005;22(11):814. **(Review)**
188. Pennington N, Gadd RJ, Green N, et al. A national survey of acute hospitals in England on their current practice in the use of femoral nerve blocks when splinting femoral fractures. *Injury*. 2012;43(6):843-845. **(Survey; 171 respondents)**
189. Wathen JE, Gao D, Merritt G, et al. A randomized controlled trial comparing a fascia iliaca compartment nerve block to a traditional systemic analgesic for femur fractures in a pediatric emergency department. *Ann Emerg Med*. 2007;50(2):162-171. **(Prospective randomized unblinded controlled trial; 55 subjects)**
190. Turner AL, Stevenson MD, Cross KP. Impact of ultrasound-guided femoral nerve blocks in the pediatric emergency department. *Pediatr Emerg Care*. 2014;30(4):227-229. **(Retrospective cohort study; 81 subjects)**
191. Graudins A, Meek R, Egerton-Warburton D, et al. The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. *Ann Emerg Med*. 2015;65(3):248-254. **(Randomized clinical trial; 76 subjects)**
192. Reynolds SL, Bryant KK, Studnek JR, et al. Randomized controlled feasibility trial of intranasal ketamine compared to intranasal fentanyl for analgesia in children with suspected extremity fractures. *Acad Emerg Med*. 2017;24(12):1430-1440. **(Randomized clinical trial; 82 subjects)**
193. Quinn K, Kriss S, Drapkin J, et al. Analgesic efficacy of intranasal ketamine versus intranasal fentanyl for moderate to severe pain in children: a prospective, randomized, double blind study. *Pediatr Emerg Care*. 2018. **(Randomized noninferiority study; 22 patients)**
194. Frey TM, Florin TA, Caruso M, et al. Effect of intranasal ketamine vs fentanyl on pain reduction for extremity injuries in children: The PRIME Randomized Clinical Trial. *JAMA Pediatr*. 2019;173(2):140-146. **(Randomized noninferiority study; 90 patients)**
195. Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. *MMWR Morb Mortal Wkly Rep*. 2016;65(50-51):1445-1452. **(Epidemiological report)**
196. Kane JM, Colvin JD, Bartlett AH, et al. Opioid-related critical care resource use in US children's hospitals. *Pediatrics*. 2018;141(4):e20173335. **(Retrospective study; 3647 subjects)**
197. Gaither JR, Leventhal JM, Ryan SA, et al. National trends in hospitalizations for opioid poisonings among children and adolescents, 1997 to 2012. *JAMA Pediatr*. 2016;170(12):1195-1201. **(Retrospective study; 13,052 subjects)**
198. Becker WC, Tobin DG, Fiellin DA. Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates. *Arch Intern Med*. 2011;171(11):1034-1036. **(Survey secondary analysis; 166,453 respondents)**
199. McCabe SE, West BT, Cranford JA, et al. Medical misuse of controlled medications among adolescents. *Arch Pediatr Adolesc Med*. 2011;165(8):729-735. **(Survey study; 2744 respondents)**
- 200.* Miech R, Johnston L, O'Malley PM, et al. Prescription opioids in adolescence and future opioid misuse. *Pediatrics*. 2015;136(5):e1169-e1177. **(Survey study; 6220 respondents)**
201. Monitto CL, Hsu A, Gao S, et al. Opioid prescribing for the treatment of acute pain in children on hospital discharge. *Anesth Analg*. 2017;125(6):2113-2122. **(Prospective observational study; 343 subjects)**

CME Questions



Take This Test Online!


Current subscribers receive CME credit absolutely free by completing the following test. Each issue includes 4 AMA PRA Category 1 Credits™, 4 ACEP Category I credits, 4 AAP Prescribed credits, or 4 AOA Category 2-A or 2-B credits. Online testing is available for current and archived issues. To receive your free CME credits for this issue, scan the QR code below with your smartphone or visit www.ebmedicine.net/P0819.



1. Which of the following medications has been shown to be safe and efficacious in children when given intranasally?
 - a. Morphine
 - b. Ibuprofen
 - c. Codeine
 - d. Fentanyl
2. The most important factor in accurate pain assessment for a verbal child is:
 - a. Choosing the best pain scale tool
 - b. Reassessing the score to monitor change during treatment
 - c. Parent reports
 - d. Nurse reports

3. Which of the following pain scales should be used to assess pain in a preverbal 2-year-old child?
 - a. Wong-Baker FACES® Pain Rating Scale
 - b. Oucher™ Pain Scale
 - c. FLACC Scale
 - d. Visual analog scale
4. Which of the following is a potential complication of the use of EMLA® in infants?
 - a. Methemoglobinemia
 - b. Carboxyhemoglobinemia
 - c. Aspirin toxicity
 - d. Lidocaine toxicity
5. A 6-year-old girl presents to the ED for vomiting. She is tachycardic and her mucous membranes appear dry. She continues to vomit despite a dose of oral ondansetron. You decide to rehydrate the patient intravenously. Which of the following would NOT be an acceptable method of local anesthesia prior to IV placement?
 - a. EMLA® cream
 - b. LMX®
 - c. Jet-injected lidocaine
 - d. Lidocaine, epinephrine, and tetracaine (LET)
6. Which of the following is NOT a side effect of lidocaine administration or overdose?
 - a. A burning sensation at the site of injection
 - b. Seizures
 - c. Dysrhythmias
 - d. Hypoxia
7. For which of the following patients should ketorolac be avoided?
 - a. A 4-year-old boy with severe asthma
 - b. A 6-year-old boy post-tonsillectomy
 - c. An 8-year-old boy with gastric ulcers
 - d. A 10-year-old boy with idiopathic hypertension
8. Which of the following analgesics has a high potential for adverse effects due to high variability in genomic profiles?
 - a. Ibuprofen
 - b. Codeine
 - c. Oxycodone
 - d. Morphine
9. A 16-year-old girl is rushed back to the resuscitation room in an unresponsive state. She was brought to the ED by her friends, who have since left. On examination, the patient is responsive only to painful stimuli. Her vital signs are: temperature, 36.1°C (97°F); heart rate, 55 beats/min; respiratory rate, 10 breaths/min; oxygen saturation, 92%; and blood pressure, 100/50 mm Hg. On examination of the patient's belongings, an empty bottle of oxycodone is found. She is given 2 mg of naloxone without improvement in her clinical status. The next step in the management of this patient is:
 - a. Order a head CT scan
 - b. Observation with cardiopulmonary monitoring
 - c. Immediate endotracheal intubation
 - d. Administration of an additional dose of naloxone
10. A 10-year-old boy presents to the ED with 2 days of abdominal pain. It started periumbilically but has since migrated to the right lower quadrant. The patient also reports vomiting and fevers. On examination, the patient is obviously uncomfortable and rates his pain a 9/10. He has a soft abdomen but has localized right lower quadrant tenderness with rebound and voluntary guarding. The next step in the management of this patient is:
 - a. Immediate general surgery consult to allow the surgery service to examine the patient's abdomen prior to administration of analgesia
 - b. Administration of IV morphine
 - c. Ultrasound of the right lower quadrant
 - d. CT scan of the abdomen with IV and oral contrast

Have you checked out POINTS & PEARLS?



Now available on the first of the month!
www.ebmedicine.net/topics



In upcoming issues of *Pediatric Emergency Medicine Practice*....

- Bronchiolitis
- Pediatric Stroke
- Mild TBI/Concussion

CME Information

Date of Original Release: August 1, 2019. Date of most recent review: July 15, 2019. Termination date: August 1, 2022.

Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME.

Credit Designation: EB Medicine designates this enduring material for a maximum of 4 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Specialty CME: Included as part of the 4 credits, this CME activity is eligible for 2 Pharmacology and 4 Pain Management CME credits.

ACEP Accreditation: *Pediatric Emergency Medicine Practice* is also approved by the American College of Emergency Physicians for 48 hours of ACEP Category I credit per annual subscription.

AAP Accreditation: This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 48 AAP credits per year. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Fellows of the American Academy of Pediatrics.

AOA Accreditation: *Pediatric Emergency Medicine Practice* is eligible for up to 48 American Osteopathic Association Category 2-A or 2-B credit hours per year.

Needs Assessment: The need for this educational activity was determined by a survey of medical staff, including the editorial board of this publication; review of morbidity and mortality data from the CDC, AHA, NCHS, and ACEP; and evaluation of prior activities for emergency physicians.

Target Audience: This enduring material is designed for emergency medicine physicians, physician assistants, nurse practitioners, and residents.

Goals: Upon completion of this activity, you should be able to: (1) demonstrate medical decision-making based on the strongest clinical evidence; (2) cost-effectively diagnose and treat the most critical ED presentations; and (3) describe the most common medicolegal pitfalls for each topic covered.

CME Objectives: Upon completion of this activity, you should be able to: (1) explain the potential harms of undertreating pain in pediatric patients; (2) select and utilize an appropriate pain scale for a pediatric patient, given his or her age and developmental level; and (3) treat acute and procedural pain in pediatric patients using the best available therapies.

Discussion of Investigational Information: As part of the journal, faculty may be presenting investigational information about pharmaceutical products that is outside Food and Drug Administration approved labeling. Information presented as part of this activity is intended solely as continuing medical education and is not intended to promote off-label use of any pharmaceutical product.

Faculty Disclosure: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: **Dr. Uspar, Dr. Black, Dr. Cico, Dr. Ali, Dr. Poonai, Dr. Mishler, Dr. Skrainka, Dr. Claudius, Dr. Horeczko, and their related parties report no significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation.**

Commercial Support: This issue of *Pediatric Emergency Medicine Practice* did not receive any commercial support.

Earning Credit: Two Convenient Methods: (1) Go online to www.ebmedicine.net/CME and click on the title of this article. (2) Mail or fax the CME Answer And Evaluation Form with your June and December issues to *Pediatric Emergency Medicine Practice*.

Hardware/Software Requirements: You will need a Macintosh or PC with Internet capabilities to access the website.

Additional Policies: For additional policies, including our statement of conflict of interest, source of funding, statement of informed consent, and statement of human and animal rights, visit <http://www.ebmedicine.net/policies>.

CEO: Stephanie Williford **Finance & HR Manager:** Robin Wilkinson **Publisher:** Suzanne Verity
Director of Editorial Quality: Dorothy Whisenhunt, MS **Senior Content Editor & CME Director:** Erica Scott
Content Editor: Cheryl Belton, PhD, ELS **Editorial Project Manager:** Angie Wallace
Office Manager: Kiana Collier **Account Executive:** Dana Stenzel
Marketing Strategist: Anna Motuz, MBA **Database Administrator:** Jose Porras

Direct all inquiries to:

EB Medicine

Phone: 1-800-249-5770 or 678-366-7933

Fax: 1-770-500-1316

PO Box 1671

Williamsport, PA 17703

E-mail: ebm@ebmedicine.net

Website: ebmedicine.net

To write a letter to the editor, please email:

iclaudiusmd@ebmedicine.net

Subscription Information

Full annual subscription: \$449 (includes 12 monthly evidence-based print issues; 48 *AMA PRA Category 1 Credits™*, 48 ACEP Category I credits, 48 AAP Prescribed credits, and 48 AOA Category 2-A or 2-B CME credits; and full online access to searchable archives and additional CME). Call 1-800-249-5770 or go to www.ebmedicine.net/subscribe to subscribe.

Individual issues: \$49 (includes 4 CME credits). Call 1-800-249-5770 or go to www.ebmedicine.net/PEMissues to order.

Group subscriptions at heavily discounted rates are also available. Contact groups@ebmedicine.net for more information.

Pediatric Emergency Medicine Practice (ISSN Print: 1549-9650, ISSN Online: 1549-9669, ACID-FREE) is published monthly (12 times per year) by EB Medicine, PO Box 1671, Williamsport, PA 17703. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. This publication is intended as a general guide and is intended to supplement, rather than substitute, professional judgment. It covers a highly technical and complex subject and should not be used for making specific medical decisions. The materials contained herein are not intended to establish policy, procedure, or standard of care. *Pediatric Emergency Medicine Practice* is a trademark of EB Medicine. Copyright © 2019 EB Medicine All rights reserved. No part of this publication may be reproduced in any form without written consent of EB Medicine. This publication is intended for the use of the individual subscriber only, and may not be copied in whole or in part or redistributed in any way without the publisher's prior written permission – including reproduction for educational purposes or for internal distribution within a hospital, library, group practice, or other entity.